<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id>
    <journal-id journal-id-type="publisher-id">narcancer</journal-id>
    <journal-title-group>
      <journal-title>NAR Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2632-8674</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10894039</article-id>
    <article-id pub-id-type="doi">10.1093/narcan/zcae008</article-id>
    <article-id pub-id-type="publisher-id">zcae008</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00030</subject>
        <subject>AcademicSubjects/SCI00980</subject>
        <subject>AcademicSubjects/SCI01060</subject>
        <subject>AcademicSubjects/SCI01140</subject>
        <subject>AcademicSubjects/SCI01180</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Cancer Data Resource</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>dbCRAF: a curated knowledgebase for regulation of radiation response in human cancer</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Jie</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Jing</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jin</surname>
          <given-names>Fangfang</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Qian</given-names>
        </name>
        <aff><institution>School of Environmental Science and Optoelectronic Technology, University of Science and Technology of China</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230026</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6107-6071</contrib-id>
        <name>
          <surname>Zhao</surname>
          <given-names>Guoping</given-names>
        </name>
        <aff><institution>Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230031</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Lijun</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230031</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Li</surname>
          <given-names>Xiaoyan</given-names>
        </name>
        <!--lixiaoyan@ahu.edu.cn-->
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3024-1705</contrib-id>
        <name>
          <surname>Xia</surname>
          <given-names>Junfeng</given-names>
        </name>
        <!--jfxia@ahu.edu.cn-->
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Cheng</surname>
          <given-names>Na</given-names>
        </name>
        <!--chengna@ahmu.edu.cn-->
        <aff><institution>School of Biomedical Engineering, Anhui Medical University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230032</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 15856916675; Email: <email>chengna@ahmu.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Junfeng Xia. Tel: +86 13966677630; Email: <email>jfxia@ahu.edu.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Xiaoyan Li. Tel: +86 13211738021; Email: <email>lixiaoyan@ahu.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-02-24">
      <day>24</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>24</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <volume>6</volume>
    <issue>1</issue>
    <elocation-id>zcae008</elocation-id>
    <history>
      <date date-type="accepted">
        <day>15</day>
        <month>2</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>10</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>9</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of NAR Cancer.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="zcae008.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Radiation therapy (RT) is one of the primary treatment modalities of cancer, with 40–60% of cancer patients benefiting from RT during their treatment course. The intrinsic radiosensitivity or acquired radioresistance of tumor cells would affect the response to RT and clinical outcomes in patients. Thus, mining the regulatory mechanisms in tumor radiosensitivity or radioresistance that have been verified by biological experiments and computational analysis methods will enhance the overall understanding of RT. Here, we describe a comprehensive database dbCRAF (<ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>) to document and annotate the factors (1,677 genes, 49 proteins and 612 radiosensitizers) linked with radiation response, including radiosensitivity, radioresistance in cancer cells and prognosis in cancer patients receiving RT. On the one hand, dbCRAF enables researchers to directly access knowledge for regulation of radiation response in human cancer buried in the vast literature. On the other hand, dbCRAF provides four flexible modules to analyze and visualize the functional relationship between these factors and clinical outcome, KEGG pathway and target genes. In conclusion, dbCRAF serves as a valuable resource for elucidating the regulatory mechanisms of radiation response in human cancers as well as for the improvement of RT options.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="zcae008figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>11835014</award-id>
        <award-id>U22A2038</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Anhui Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003995</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2208085QF193</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Fund for Excellent Young Scholars</institution>
            <institution-id institution-id-type="DOI">10.13039/100014717</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>12122510</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="9"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>As an intricate disease, cancer has greatly reduced human life expectancy worldwide (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). Radiation therapy (RT) is one of the prominent modalities for treating intricate diseases, and it can be used alone or in combination with other treatments to cure tumors and relieve tumor-related symptoms in cancer patients (<xref rid="B3" ref-type="bibr">3</xref>). However, the effects of RT are not specific to tumor cells and may cause side effects or toxicity to surrounding exposed organs and tissues (e.g. RT injury, secondary cancer) (<xref rid="B3" ref-type="bibr">3–5</xref>). Therefore, it is important to examine the molecular mechanism of radiation response that enhances tumor killing while reducing toxicity to surrounding normal tissues, which can ensure better therapeutic outcomes and provide meaningful improvement for cancer patients (<xref rid="B6" ref-type="bibr">6–8</xref>).</p>
    <p>Many researchers have dedicated their efforts to studying the molecular mechanisms of radiosensitivity, radioresistance in human tumor cell lines or prognosis in cancer patients receiving RT, but these valuable findings are scattered across multiple sources (<xref rid="B9" ref-type="bibr">9–11</xref>). To be specific, emerging evidence in the literature has connected more coding genes and various types of non-coding RNAs (ncRNAs) like microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) to radioresistance and radiosensitivity in human cancers. For example, Han <italic toggle="yes">et al.</italic> demonstrated that down-regulation of <italic toggle="yes">PVT1</italic> inhibits radioresistance in nasopharyngeal carcinoma cells (<xref rid="B12" ref-type="bibr">12</xref>). Wang et al. found that circ_0067835 knockdown suppresses colorectal cancer (CRC) progression and strengthens CRC cell radiosensitivity (<xref rid="B13" ref-type="bibr">13</xref>). Additionally, Wen <italic toggle="yes">et al.</italic> constructed the dbCRSR database, which contains 395 coding genes, 119 miRNAs and 306 chemical compounds that can modulate radiosensitivity (<xref rid="B14" ref-type="bibr">14</xref>). Moreover, with the development of sequencing technology, there has been extensive literature using computational analysis methods to elucidate the complex relationship between genes and cancer prognosis with RT (<xref rid="B15" ref-type="bibr">15–19</xref>). These findings also provide valuable insights for improving the clinical outcomes of RT. To sum up, the lack of an effective collection of these scattered data makes it difficult to obtain an overarching understanding of prior research on the molecular mechanisms of radiation response, thus hampering the further progress of RT treatment.</p>
    <p>To meet these needs, we developed an informative and functional database (dbCRAF, <ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>), which contains various factors (1,677 genes, 612 radiosensitizers and 49 proteins) associated with radiosensitivity, radioresistance in cancer cells and prognosis in cancer patients receiving RT. In addition, we collated miRNA-target, lncRNA-target, circRNA-target and drug-target interactions for ncRNAs and radiosensitizers associated with radiation response, allowing users to construct radiation response interaction networks. Furthermore, four analytics modules were designed to enable users to extract key factors or potential modulators affecting radiation response based on the collected data. In brief, dbCRAF aspires to be a one-stop online service for integrating and analyzing valuable information on cellular radiation response.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <p>This part introduces data collection and curation, interaction data processing, data analysis and visualization, and database design and web interface implementation for the dbCRAF database.</p>
    <sec id="SEC2-1">
      <title>Data collection and curation</title>
      <p>To conduct a systematic review of the literature, we first searched PubMed articles published between January 2000 to February 2022 using a list of keywords (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>) related to radiosensitivity, radioresistance and RT prognosis prediction. Second, we performed full-text screening to assess the eligibility of papers and extracted key information from the relevant articles using PubTator (<xref rid="B20" ref-type="bibr">20</xref>), including publication information, the factor (genes, proteins, radiosensitizers) that could regulate radiation response, cancer type, the regulation mode of each factor, gene expression fold change, the cytotoxicity of radiosensitizers, the cell line name, the type of model organism, the type of ray, the cancer tissue source, sample size, collection time, the type of radiotherapy and survival endpoint. Notably, we defined each evidence that linked a factor to radiation response in cancer as an association. Third, to guarantee consistent names for all obtained factors and related cancers, we unified the gene names using the gene symbol-alias conversion table from the HGNC database (2022.4.12 version) (<xref rid="B21" ref-type="bibr">21</xref>), and radiosensitizer using ‘Generic Name’ from the DrugBank database (<xref rid="B22" ref-type="bibr">22</xref>). Fourth, we harmonized cancer names with disease terms in the MeSH database (2022.8.8 version) according to the occurrence location of the tumor (<xref rid="B23" ref-type="bibr">23</xref>). Fifth, we retained the original content of the type of RT, cancer tissue source, the type of ray and survival endpoint due to the presence of multiple descriptions in many publications. This decision enables the database to provide a more comprehensive representation of the data. Lastly, we added the subcellular location annotation from the GeneCards database, exploring the relationship between different subcellular structures and gene products related to radiation response (<xref rid="B24" ref-type="bibr">24</xref>).</p>
      <p>All the above information has been processed using python or R scripts, and manually verified by at least two individuals to ensure its accuracy. The scripts employed for processing could be downloaded in dbCRAF.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Interaction data processing</title>
      <p>To enable users to mine more information based on the associations collected in dbCRAF and to comprehend the mechanisms underlying radiation response regulation, we gathered four kinds of interaction data and target genes of miRNAs, lncRNAs, circRNAs, and radiosensitizers related to radiation response, as shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>. We first collected the miRNA-target interactions of Homo sapiens with the support type of ‘Functional miRNA-target interactions’ from the miRTarBase database (<xref rid="B25" ref-type="bibr">25</xref>). Then, we obtained the lncRNA-target interactions in human that were confirmed by low-throughput methods such as RT-qPCR and western blot from LncRNA2Target database (<xref rid="B26" ref-type="bibr">26</xref>). Next, we organized the intersection of potential circRNA-target interactions from the CircInteractome (<xref rid="B27" ref-type="bibr">27</xref>) and Circbank (<xref rid="B28" ref-type="bibr">28</xref>) databases to improve confidence of these results derived from related predictive tools. Moreover, radiosensitizer (drug)–target interactions were retrieved from the DrugBank, PharmGKB (<xref rid="B29" ref-type="bibr">29</xref>) and CMap (<xref rid="B30" ref-type="bibr">30</xref>) databases. Finally, we also integrated protein-protein interaction (PPI) data for the target genes and the genes recorded in dbCRAF based on the STRING database (<xref rid="B31" ref-type="bibr">31</xref>) to infer the overall regulatory network.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Data analysis and visualization</title>
      <p>To further explore the association data and four kinds of interaction data, we constructed four analysis blocks equipped with visual aids such as Word Cloud graphs, Kaplan–Meier survival analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (<xref rid="B32" ref-type="bibr">32</xref>) and interaction network visualization. First, Word Cloud allows users to count and visualize the associations between factors and cancer recorded in dbCRAF. The size of each factor's representation in the Word Cloud is proportional to the number of associations it has. This visual representation helps users identify factors that have a higher number of associations. Second, we collected the RNA-seq and clinical data from the Cancer Genome Atlas (TCGA) database (<xref rid="B33" ref-type="bibr">33</xref>), and investigated whether the expression levels of miRNAs or mRNAs recorded in dbCRAF affected the clinical prognosis of samples receiving RT at different tumor stages (stages I–IV) in one or more types of cancer. The results are presented using Kaplan-Meier survival curves, enabling users to assess the impact of these factors on patient outcomes. Third, KEGG pathway enrichment analysis supports users to annotate genes related to radiation response according to the type of pathway involved, and the results are presented in the form of bubble chart. This visualization helps users understand the functional roles of the identified factors by displaying enriched pathways. Finally, interaction network visualization enables users to describe the interaction relationships of factors in dbCRAF, thus facilitating the screening of key genes and potential modulators of radiation response.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Database design and web interface implementation</title>
      <p>The dbCRAF website was developed using Apache Tomcat Server (<ext-link xlink:href="http://tomcat.apache.org" ext-link-type="uri">http://tomcat.apache.org</ext-link>), Flask (<ext-link xlink:href="https://pypi.org/project/Flask" ext-link-type="uri">https://pypi.org/project/Flask</ext-link>) and MySQL (<ext-link xlink:href="http://www.mysql.org" ext-link-type="uri">http://www.mysql.org</ext-link>). We used Python 3.10 for server-side scripting to provide query and computation support in the backend of the database, and used HTML5, CSS3, JQuery (version 1.12.4), AJAX, ECharts (<ext-link xlink:href="https://echarts.apache.org" ext-link-type="uri">https://echarts.apache.org</ext-link>), dataTables (<ext-link xlink:href="https://datatables.net" ext-link-type="uri">https://datatables.net</ext-link>) and BootStrap (<ext-link xlink:href="https://getbootstrap.com" ext-link-type="uri">https://getbootstrap.com</ext-link>) frameworks to develop a user-friendly interactive web interface. Additionally, we employed various Python packages for the implementation of the ‘Analysis’ interface, including lifelines (version 0.27.0), gseapy (version 0.10.8), matplotlib (version 3.5.2), numpy (version 1.22.4), pandas (version 1.4.2) and matplotlib (version 3.5.2). We recommend visiting dbCRAF by a web browser such as Google Chrome, Microsoft Edge or Firefox.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Database content summary</title>
      <p>After excluding duplicate articles with the same PubMed ID or title, we retained &gt;10,000 records. Particularly, we classifies those literature about exploring the molecular mechanism of radiosensitivity and radioresistance through over-expression or knock-down assays as ‘Experiment’, and labels those about predicting radiation response and RT prognosis of cancer patients through computational analysis as ‘Prediction’. We then screened the full-text records to assess their relevance and extracted key information. dbCRAF currently contains 4,448 association entries between factors and cancer from 2,670 publications and it covers 1,677 genes, 612 radiosensitizers, and 49 proteins linked with 30 types of cancer.</p>
      <p>In comparison to the dbCRSR database, the dbCRAF database encompassed literature with a longer time span, as indicated in Table <xref rid="tbl1" ref-type="table">1</xref>. Additionally, dbCRAF provided information on multiple mechanisms of radiation response, resulting in a greater number of associations between factors and radiation response in cancer being recorded. Moreover, dbCRAF included descriptions of the various modes through which each factor modulated the radiation response in cancer. These modes included the addition of radiosensitizers, occurrence of gene mutation, changes in gene expression level, gene methylation status or protein expression. In summary, the information contained in dbCRAF is more comprehensive.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>The statistic and comparison of dbCRSR and dbCRAF databases</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Term</th>
              <th rowspan="1" colspan="1">dbCRSR</th>
              <th rowspan="1" colspan="1">dbCRAF</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Database function</td>
              <td rowspan="1" colspan="1">Download, search</td>
              <td rowspan="1" colspan="1">Download, search, analysis</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication source</td>
              <td rowspan="1" colspan="1">PubMed</td>
              <td rowspan="1" colspan="1">PubMed</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication date</td>
              <td rowspan="1" colspan="1">January 2008–October 2017</td>
              <td rowspan="1" colspan="1">January 2000–February 2022</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication number</td>
              <td rowspan="1" colspan="1">1,072</td>
              <td rowspan="1" colspan="1">2,670</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Association number</td>
              <td rowspan="1" colspan="1">1,132</td>
              <td rowspan="1" colspan="1">4,448</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Mechanism</td>
              <td rowspan="1" colspan="1">Experiment (RS<sup>a</sup>)</td>
              <td rowspan="1" colspan="1">Experiment (RS/RR<sup>b</sup>), prediction</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Factor type</td>
              <td rowspan="1" colspan="1">mRNA (395), miRNA (119), compound (306)</td>
              <td rowspan="1" colspan="1">Gene (1,677), protein (49), radiosensitizer (612)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T1TFN1">
            <p><sup>a</sup>Radiosensitivity.</p>
          </fn>
          <fn id="T1TFN2">
            <p><sup>b</sup>Radioresistance.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>In addition, we made three findings by analyzing the 4,448 associations recorded in dbCRAF. First, the number of studies that focused on molecular mechanisms of radiation response showed an increasing trend year by year (Figure <xref rid="F1" ref-type="fig">1A</xref>). This indicates the growing interest in understanding the molecular mechanisms of radiation response and its potential applications in cancer treatment. Meanwhile, recent studies published since 2018 have integrated the analysis of large genomic or transcriptome datasets with biological experiments to efficiently screen and verify genes of interest. This approach eliminated the limitations imposed by prior knowledge or assumptions and provided stronger evidence for identifying potential new associations between factors and cancer. Second, more than half of the associations were related to head and neck neoplasms, lung neoplasms, and breast neoplasms (Figure <xref rid="F1" ref-type="fig">1B</xref>), which might be due to their higher incidence or the wider use of RT options and thus leading to more relevant studies (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B34" ref-type="bibr">34–36</xref>). Third, the largest number of factors involved in regulating cancer radiation response were genes, followed by radiosensitizers (Figure <xref rid="F1" ref-type="fig">1C</xref>). Lastly, we separately counted the five categories of genes and found that in addition to protein-coding genes, there has been an increasing amount of ncRNAs documented in the radiation response-related literature (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Summary of dbCRAF contents. (<bold>A</bold>) Statistics of publication information. (<bold>B</bold>) Statistics of association data with each cancer type. (<bold>C</bold>) Statistics of association data with each kind of factor.</p>
        </caption>
        <graphic xlink:href="zcae008fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Hot protein-coding gene and enriched pathways</title>
      <p>After counting 2,658 associations between coding gene and cancer, we found a total of 1,308 coding genes. Among them, <italic toggle="yes">HIF1A</italic>, <italic toggle="yes">EGFR</italic>, and <italic toggle="yes">ATM</italic> were the most extensively studied coding genes, and their expression levels could influence the response of multiple tumors to radiation (Figure <xref rid="F2" ref-type="fig">2A</xref>). Next, we grouped all coding genes (793 versus 666) collected in ‘Experiment’ and ‘Prediction’ articles respectively, and obtained 151 genes shared between them (Figure <xref rid="F2" ref-type="fig">2B</xref>). This indicates that both biological experiments and computational methods have identified these 151 genes as potential genetic biomarkers for prognosis, radiosensitivity or radioresistance in human cancer. This finding suggests the possibility of optimizing RT effects based on a patient's genomic profiles and intrinsic radiosensitivity (<xref rid="B39" ref-type="bibr">39</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Overview of protein-coding gene-cancer associations. (<bold>A</bold>) Word cloud of all protein-coding genes, where there is more literature evidence for genes are displayed using a larger font size. (<bold>B</bold>) Number of coding genes derived from Experiment or Prediction publications. (<bold>C</bold>) The top 20 KEGG enrichment pathways of coding genes with experimental evidence (793 genes) or only computational analysis results (515 genes).</p>
        </caption>
        <graphic xlink:href="zcae008fig2" position="float"/>
      </fig>
      <p>Additionally, we analyzed 515 coding genes related to cancer prognosis identified in the ‘Prediction’ articles but not in the ‘Experiment’ articles to uncover more potential genetic biomarkers. Specifically, we performed the KEGG pathway enrichment analysis on the two groups of coding genes (793 versus 515) with or without experimental evidence of regulating radiation response. The results showed that four pathways were the same in both groups of genes, including IL-17 signaling pathway, neurodegeneration-multiple diseases pathways, pathways in cancer, and proteoglycans in cancer (Figure <xref rid="F2" ref-type="fig">2C</xref>). In summary, 137 of the 515 coding genes are involved in one or more of these four pathways (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>), and it is likely that they regulate radiosensitivity, radioresistance or prognosis in cancer through their involvement in these functional pathways.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Noncoding RNA, radiosensitizer and their target genes analysis</title>
      <p>Non-coding RNAs and radiosensitizers typically exert regulatory function in radiation response via interacting with target genes. Therefore, we collected and analyzed interaction data of ncRNAs and radiosensitizers related to radiation response from various databases (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). First, we counted the most studied miRNAs, lncRNAs and radiosensitizers based on association data documented in dbCRAF. As shown in Figure <xref rid="F3" ref-type="fig">3A</xref>, the top four ncRNAs and radiosensitizers were all involved in modulating radiation response in one or more cancers. Notably, there were only 31 associations between circRNA and cancer, making it difficult to sort circRNAs according to the study frequency. Second, we integrated all target genes and interaction data of ncRNAs and radiosensitizers linked with radiation response, including miRNA-target interactions, lncRNA-target interactions, circRNA–target interactions and radiosensitizer-target interactions. Interestingly, almost 25% of the target genes have been documented to be associated with radiation response (Figure <xref rid="F3" ref-type="fig">3B</xref>). Third, we counted the top 20 target genes that appeared most frequently in the interaction data and collected evidence for their regulation of radiation response. We hypothesized that target genes that appear more frequently in the interaction data are more likely to regulate radiosensitivity or radioresistance. Coincidentally, 19 of the top 20 target genes have been experimentally confirmed to regulate the radiation response (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>), with only the <italic toggle="yes">FOXO1</italic> gene lacking study evidence.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Statistics related to non-coding RNAs, radiosensitizers and their target interactions. (<bold>A</bold>) Statistics of the associations about top four miRNAs, lncRNAs and radiosensitizers, where more frequent associations are displayed using a thicker line. (<bold>B</bold>) Venn diagram of genes recorded in dbCRAF and all target genes. (<bold>C</bold>) Sankey diagram of FOXO1–miRNA–cancer associations.</p>
        </caption>
        <graphic xlink:href="zcae008fig3" position="float"/>
      </fig>
      <p>Therefore, we combined miRNA-target (<italic toggle="yes">FOXO1</italic>) interactions and relevant associations between miRNA and cancer recorded in dbCRAF to map <italic toggle="yes">FOXO1</italic>-miRNA-cancer associations. The results showed that <italic toggle="yes">FOXO1</italic> may be associated with radiation responses in lung neoplasms and head and neck neoplasms (Figure <xref rid="F3" ref-type="fig">3C</xref>). Although there is no direct evidence suggesting that <italic toggle="yes">FOXO1</italic> regulates the radiation response of cancer cells, <italic toggle="yes">FOXO1</italic> is still an important factor in cancer processes based on its inclusion in the oncogene and tumor suppressor gene list from the Cancer Gene Census project (<xref rid="B40" ref-type="bibr">40</xref>). Additionally, Zhou <italic toggle="yes">et al.</italic> found that <italic toggle="yes">TCF19</italic> could promote cell proliferation in non‐small cell lung cancer by inhibiting <italic toggle="yes">FOXO1</italic> (<xref rid="B41" ref-type="bibr">41</xref>). Gong <italic toggle="yes">et al.</italic> also showed that the <italic toggle="yes">AKBA</italic> gene inhibited radioresistance in lung cancer through the regulation of the <italic toggle="yes">AKT</italic>/<italic toggle="yes">FOXO1</italic>/<italic toggle="yes">p21</italic> axis (<xref rid="B42" ref-type="bibr">42</xref>). These findings support our conclusion that <italic toggle="yes">FOXO1</italic> may be closely related to the occurrence and prognosis of RT in lung cancer.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Key dbCRAF modules and user cases</title>
      <p>dbCRAF provides a comprehensive collection of high-quality data, including association data between factors and radiation response in cancer as well as interaction data between factors and target genes. All data are freely available through the Download module, and users can browse and analyze the data using the Data-Matrix, Search, and Analysis modules on the dbCRAF website (<ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>), as shown in Figure <xref rid="F4" ref-type="fig">4</xref>.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Schematic of dbCRAF.</p>
        </caption>
        <graphic xlink:href="zcae008fig4" position="float"/>
      </fig>
      <p>The ‘Data-Matrix’ page is an interactive and digitized table organized by factors (rows) associated with radiation response and cancer types (columns), allowing users to quickly navigate all association entries.</p>
      <p>For the Search page, dbCRAF provides user-friendly search options supporting automatic retrieval of association data recorded in dbCRAF under multiple cancer types. In addition, users can query the related data with different evidence in three ways: ‘By All’, ‘By Experiment’ and ‘By Prediction’. Furthermore, users can click the corresponding entry to view all detailed information, such as key sentences and biological experiment settings.</p>
      <p>On the Analysis page, dbCRAF supports four practical analysis functions to answer common biological questions. Users can perform word cloud, KEGG pathway enrichment analysis, and interaction network visualization using a list of factors related to radiation response along with their interaction data. Kaplan-Meier survival analysis is implemented with the miRNA-seq, mRNA-seq and clinical data of cancer patients treated with RT in the TCGA database.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>To the best of our knowledge, dbCRAF is the first database to furnish association data between factor and human cancer related to multiple radiation response regulatory mechanisms, including radiosensitivity, radioresistance, and prognosis of RT in cancer patients. At the same time, we gathered the interaction data concerning ncRNAs and radiosensitizers linked to radiation response. On top of that, dbCRAF allows users to analyze the above information, and provides an all-in-one service for the retrieval, analysis, and visualization of human cancer radiation response factors related to human cancer.</p>
    <p>For this study, we ran statistical analyses of association data retrieved from the PubMed literature, interaction data and target genes derived from multiple databases, respectively, to provide more guidance for researchers. Moreover, we found that out of the 666 coding genes related to tumor RT prognosis, a total of 151 genes had been validated by over-expression or knock-down assays. These assays have demonstrated their potential influence on the radiosensitivity or radioresistance of cancer cell lines. Therefore, it is essential to perform biological experiments on the remaining 515 genes to investigate their regulatory mechanism of response to radiation in human cancer cells. Additionally, regarding the data of miRNA-target interactions, we observed that hsa-miR-195–5p interacted with <italic toggle="yes">BCL2</italic>, the target gene with the most interaction data (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>). Interestingly, earlier studies revealed that hsa-miR-195-5p could enhance the radiosensitivity of breast cancer cells by repressing the expression of <italic toggle="yes">BCL2</italic> (<xref rid="B43" ref-type="bibr">43</xref>). Consequently, it is feasible to discover more potential biomarkers of radiation response by utilizing both information including the associations between factor and cancer in dbCRAF and corresponding interactions between factor and target gene.</p>
    <p>This work also has several limitations that require further exploration. On the one hand, the current database lacks information on radiation toxicity, the change of radiosensitivity, treatment options and machines. It is necessary to explore and include this additional information from relevant literature or databases in the future to enhance the understanding of radiation response. On the other hand, we observed that more than half of the associations are linked to head and neck neoplasms, lung neoplasms and breast neoplasms. This disproportionate distribution may introduce bias in the database and the biological information it contains. To address this issue, we are considering implementing mechanisms such as weighting, where cancer types with fewer associations are given greater weight when inferring potential associations between genes and radiation response in cancer. Furthermore, it is crucial to supplement associations of cancer types with limited data by incorporating information from additional sources like Web of Science and Scopus. These efforts will contribute to a more comprehensive representation of radiation response and help mitigate potential bias across various types of cancer.</p>
    <p>In conclusion, with the collated data and the implementation of four online analysis tools, dbCRAF is not only an integrated resource, but also a web server for mining the potential molecular mechanisms of radiation response. The data and the functions of dbCRAF may be provide new perspectives on the development of RT therapeutics for human cancer.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>zcae008_supplemental_file</label>
      <media xlink:href="zcae008_supplemental_file.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>The authors acknowledge the High-performance Computing Platform of Anhui University for providing computing resources. We would like to thank the Xia laboratory members for their participation in the data collection in this work.</p>
    <p><italic toggle="yes">Author contributions</italic>: J. Liu: Data curation, Methodology, Writing-original draft. J. Li.: Database design, Writing - original draft. F. Jin: Database design. Q. Li: Methodology. G. Zhao: Writing-review &amp; editing. L. Wu: Writing-review &amp; editing. X. Li: Supervision, Writing-review &amp; editing. J. Xia: Conceptualization, Supervision, Writing-review &amp; editing. N. Cheng: Conceptualization, Supervision, Writing-review &amp; editing.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>No new data were generated or analysed in support of this research.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcae008#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Cancer Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Natural Science Foundation of China [11835014, U22A2038]; Natural Science Foundation of Anhui Province [2208085QF193]; National Science Fund for Excellent Young Scholars [12122510].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sung</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J.</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Laversanne</surname><given-names>M.</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bray</surname><given-names>F.</given-names></string-name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin.</source><year>2021</year>; <volume>71</volume>:<fpage>209</fpage>–<lpage>249</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bray</surname><given-names>F.</given-names></string-name>, <string-name><surname>Laversanne</surname><given-names>M.</given-names></string-name>, <string-name><surname>Weiderpass</surname><given-names>E.</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I.</given-names></string-name></person-group><article-title>The ever-increasing importance of cancer as a leading cause of premature death worldwide</article-title>. <source>Cancer-Am Cancer Soc.</source><year>2021</year>; <volume>127</volume>:<fpage>3029</fpage>–<lpage>3030</lpage>.</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>K.</given-names></string-name>, <string-name><surname>Tepper</surname><given-names>J.E.</given-names></string-name></person-group><article-title>Radiation therapy-associated toxicity: etiology, management, and prevention</article-title>. <source>CA Cancer J Clin.</source><year>2021</year>; <volume>71</volume>:<fpage>437</fpage>–<lpage>454</lpage>.<pub-id pub-id-type="pmid">34255347</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bentzen</surname><given-names>S.M.</given-names></string-name></person-group><article-title>Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology</article-title>. <source>Nat. Rev. Cancer</source>. <year>2006</year>; <volume>6</volume>:<fpage>702</fpage>–<lpage>713</lpage>.<pub-id pub-id-type="pmid">16929324</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quon</surname><given-names>H.</given-names></string-name>, <string-name><surname>McNutt</surname><given-names>T.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bowers</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Lakshminarayanan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Han</surname><given-names>P.J.</given-names></string-name>, <string-name><surname>Hui</surname><given-names>X.</given-names></string-name>, <string-name><surname>Moore</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Needs and challenges for radiation oncology in the era of precision medicine</article-title>. <source>Int. J Radiat Oncol.</source><year>2019</year>; <volume>103</volume>:<fpage>809</fpage>–<lpage>817</lpage>.</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bernier</surname><given-names>J.</given-names></string-name></person-group><article-title>Precision medicine for early breast cancer radiotherapy: opening up new horizons?</article-title>. <source>Crit. Rev. Oncol. Hemat.</source><year>2017</year>; <volume>113</volume>:<fpage>79</fpage>–<lpage>82</lpage>.</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>H.H.W.</given-names></string-name>, <string-name><surname>Kuo</surname><given-names>M.T.</given-names></string-name></person-group><article-title>Improving radiotherapy in cancer treatment: promises and challenges</article-title>. <source>Oncotarget</source>. <year>2017</year>; <volume>8</volume>:<fpage>62742</fpage>–<lpage>62758</lpage>.<pub-id pub-id-type="pmid">28977985</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marks</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Yorke</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ten Haken</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Constine</surname><given-names>L.S.</given-names></string-name>, <string-name><surname>Eisbruch</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bentzen</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Nam</surname><given-names>J.</given-names></string-name>, <string-name><surname>Deasy</surname><given-names>J.O.</given-names></string-name></person-group><article-title>Use of normal tissue complication probability models in the clinic</article-title>. <source>Int. J Radiat. Oncol.</source><year>2010</year>; <volume>76</volume>:<fpage>S10</fpage>–<lpage>S19</lpage>.</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Galeaz</surname><given-names>C.</given-names></string-name>, <string-name><surname>Totis</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bisio</surname><given-names>A.</given-names></string-name></person-group><article-title>Radiation resistance: a matter of transcription factors</article-title>. <source>Front. Oncol.</source><year>2021</year>; <volume>11</volume>:<fpage>662840</fpage>.<pub-id pub-id-type="pmid">34141616</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>F.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name></person-group><article-title>Radiation-induced cell death and its mechanisms</article-title>. <source>Health Phys.</source><year>2022</year>; <volume>123</volume>:<fpage>376</fpage>–<lpage>386</lpage>.<pub-id pub-id-type="pmid">36069830</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xi</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>D.H.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>An omics-to-omics joint knowledge association subtensor model for radiogenomics cross-modal modules from genomics and ultrasonic images of breast cancers</article-title>. <source>Comput. Biol. Med.</source><year>2023</year>; <volume>155</volume>:<fpage>106672</fpage>.<pub-id pub-id-type="pmid">36805226</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name></person-group><article-title>PVT1 mediates cell proliferation, apoptosis and radioresistance in nasopharyngeal carcinoma through regulating miR-515-5p/PIK3CA Axis</article-title>. <source>Cancer Manag. Res.</source><year>2020</year>; <volume>12</volume>:<fpage>10077</fpage>–<lpage>10090</lpage>.<pub-id pub-id-type="pmid">33116864</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>P.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y.M.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name></person-group><article-title>Circ_0067835 knockdown enhances the radiosensitivity of colorectal cancer by miR-296-5p/IGF1R axis</article-title>. <source>Oncotargets Ther.</source><year>2021</year>; <volume>14</volume>:<fpage>491</fpage>–<lpage>502</lpage>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wen</surname><given-names>P.B.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>X.B.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>B.</given-names></string-name>, <string-name><surname>Tao</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>G.P.</given-names></string-name></person-group><article-title>dbCRSR: a manually curated database for regulation of cancer radiosensitivity</article-title>. <source>Database-Oxford</source>. <year>2018</year>; <volume>2018</volume>:<fpage>bay049</fpage>.<pub-id pub-id-type="pmid">29860480</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Principe</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zapater-Latorre</surname><given-names>E.</given-names></string-name>, <string-name><surname>Arribas</surname><given-names>L.</given-names></string-name>, <string-name><surname>Garcia-Miragall</surname><given-names>E.</given-names></string-name>, <string-name><surname>Bagan</surname><given-names>J.</given-names></string-name></person-group><article-title>Salivary IL-8 as a putative predictive biomarker of radiotherapy response in head and neck cancer patients</article-title>. <source>Clin. Oral. Invest.</source><year>2022</year>; <volume>26</volume>:<fpage>437</fpage>–<lpage>448</lpage>.</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>L.</given-names></string-name>, <string-name><surname>Geng</surname><given-names>R.R.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y.F.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Z.X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S.B.</given-names></string-name></person-group><article-title>An 11-gene signature based on treatment responsiveness pedicts radiation therapy survival benefit among breast cancer patients</article-title>. <source>Front. Oncol.</source><year>2022</year>; <volume>11</volume>:<fpage>816053</fpage>.<pub-id pub-id-type="pmid">35071020</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Gu</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Z.Q.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>X.C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Q.Y.</given-names></string-name></person-group><article-title>A radioresponse-related lncRNA biomarker signature for risk classification and prognosis prediction in non-small-cell lung cancer</article-title>. <source>J. Oncol.</source><year>2021</year>; <volume>2021</volume>:<fpage>4338838</fpage>.<pub-id pub-id-type="pmid">34594376</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>C.D.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name></person-group><article-title>RTPDB: a database providing associations between genetic variation or expression and cancer prognosis with radiotherapy-based treatment</article-title>. <source>Database</source>. <year>2018</year>; <volume>2018</volume>:<fpage>bay118</fpage>.<pub-id pub-id-type="pmid">30376049</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xi</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>X.G.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>A.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>Inferring subgroup-specific driver genes from heterogeneous cancer samples via subspace learning with subgroup indication</article-title>. <source>Bioinformatics</source>. <year>2020</year>; <volume>36</volume>:<fpage>1855</fpage>–<lpage>1863</lpage>.<pub-id pub-id-type="pmid">31626284</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Allot</surname><given-names>A.</given-names></string-name>, <string-name><surname>Leaman</surname><given-names>R.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Z.Y.</given-names></string-name></person-group><article-title>PubTator central: automated concept annotation for biomedical full text articles</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>W587</fpage>–<lpage>W593</lpage>.<pub-id pub-id-type="pmid">31114887</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tweedie</surname><given-names>S.</given-names></string-name>, <string-name><surname>Braschi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>T.E.M.</given-names></string-name>, <string-name><surname>Seal</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Yates</surname><given-names>B.</given-names></string-name>, <string-name><surname>Bruford</surname><given-names>E.A.</given-names></string-name></person-group><article-title>Genenames.org: the HGNC and VGNC resources in 2021</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D939</fpage>–<lpage>D946</lpage>.<pub-id pub-id-type="pmid">33152070</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lipscomb</surname><given-names>C.E.J.B.o.t.M.L.A.</given-names></string-name></person-group><article-title>Medical subject headings (MeSH)</article-title>. <source>Bull. Med. Libr. Assoc.</source><year>2000</year>; <volume>88</volume>:<fpage>265</fpage>–<lpage>266</lpage>.<pub-id pub-id-type="pmid">10928714</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Safran</surname><given-names>M.</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Twik</surname><given-names>M.</given-names></string-name>, <string-name><surname>BarShir</surname><given-names>R.</given-names></string-name>, <string-name><surname>Stein</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Dahary</surname><given-names>D.</given-names></string-name>, <string-name><surname>Fishilevich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lancet</surname><given-names>D</given-names></string-name></person-group><source>Practical Guide to Life Science Databases</source>. <year>2021</year>; <publisher-name>Springer</publisher-name><fpage>27</fpage>–<lpage>56</lpage>.</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y.C.D.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y.X.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>J.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.L.</given-names></string-name>, <string-name><surname>Wen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zuo</surname><given-names>H.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D222</fpage>–<lpage>D230</lpage>.<pub-id pub-id-type="pmid">34850920</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P.P.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>Q.H.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>W.Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>LncRNA2Target v2.0: a comprehensive database for target genes of lncRNAs in human and mouse</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D140</fpage>–<lpage>D144</lpage>.<pub-id pub-id-type="pmid">30380072</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dudekulay</surname><given-names>D.B.</given-names></string-name>, <string-name><surname>Panda</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Grammatikakis</surname><given-names>I.</given-names></string-name>, <string-name><surname>De</surname><given-names>S.</given-names></string-name>, <string-name><surname>Abdelmohsen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Gorospe</surname><given-names>M.</given-names></string-name></person-group><article-title>CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs</article-title>. <source>Rna Biol.</source><year>2016</year>; <volume>13</volume>:<fpage>34</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">26669964</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B.B.</given-names></string-name>, <string-name><surname>Ding</surname><given-names>X.M.</given-names></string-name></person-group><article-title>Circbank: a comprehensive database for circRNA with standard nomenclature</article-title>. <source>Rna Biol.</source><year>2019</year>; <volume>16</volume>:<fpage>899</fpage>–<lpage>905</lpage>.<pub-id pub-id-type="pmid">31023147</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whirl-Carrillo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huddart</surname><given-names>R.</given-names></string-name>, <string-name><surname>Gong</surname><given-names>L.</given-names></string-name>, <string-name><surname>Sangkuhl</surname><given-names>K.</given-names></string-name>, <string-name><surname>Thorn</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Whaley</surname><given-names>R.</given-names></string-name>, <string-name><surname>Klein</surname><given-names>T.E.</given-names></string-name></person-group><article-title>An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine</article-title>. <source>Clin. Pharmacol. Ther.</source><year>2021</year>; <volume>110</volume>:<fpage>563</fpage>–<lpage>572</lpage>.<pub-id pub-id-type="pmid">34216021</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X.D.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname><given-names>J.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szklarczyk</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gable</surname><given-names>A.L.</given-names></string-name>, <string-name><surname>Nastou</surname><given-names>K.C.</given-names></string-name>, <string-name><surname>Lyon</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kirsch</surname><given-names>R.</given-names></string-name>, <string-name><surname>Pyysalo</surname><given-names>S.</given-names></string-name>, <string-name><surname>Doncheva</surname><given-names>N.T.</given-names></string-name>, <string-name><surname>Legeay</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Bork</surname><given-names>P.</given-names></string-name></person-group><article-title>The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D605</fpage>–<lpage>D612</lpage>.<pub-id pub-id-type="pmid">33237311</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Goto</surname><given-names>S.</given-names></string-name></person-group><article-title>KEGG: Kyoto encyclopedia of genes and genomes</article-title>. <source>Nucleic Acids Res.</source><year>2000</year>; <volume>28</volume>:<fpage>27</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">10592173</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomczak</surname><given-names>K.</given-names></string-name>, <string-name><surname>Czerwińska</surname><given-names>P.</given-names></string-name>, <string-name><surname>Wiznerowicz</surname><given-names>M.</given-names></string-name></person-group><article-title>Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge</article-title>. <source>Contemp Oncol.</source><year>2015</year>; <volume>2015</volume>:<fpage>68</fpage>–<lpage>77</lpage>.</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chow</surname><given-names>L.Q.</given-names></string-name></person-group><article-title>Head and neck cancer</article-title>. <source>N. Engl. J Med.</source><year>2020</year>; <volume>382</volume>:<fpage>60</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">31893516</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lemjabbar-Alaoui</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hassan</surname><given-names>O.U.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.W.</given-names></string-name>, <string-name><surname>Buchanan</surname><given-names>P.</given-names></string-name></person-group><article-title>Lung cancer: biology and treatment options</article-title>. <source>Bba-Rev Cancer</source>. <year>2015</year>; <volume>1856</volume>:<fpage>189</fpage>–<lpage>210</lpage>.</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al-Mahmood</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sapiezynski</surname><given-names>J.</given-names></string-name>, <string-name><surname>Garbuzenko</surname><given-names>O.B.</given-names></string-name>, <string-name><surname>Minko</surname><given-names>T.</given-names></string-name></person-group><article-title>Metastatic and triple-negative breast cancer: challenges and treatment options</article-title>. <source>Drug Deliv. Transl. Re</source>. <year>2018</year>; <volume>8</volume>:<fpage>1483</fpage>–<lpage>1507</lpage>.</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ebahimzadeh</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shoorei</surname><given-names>H.</given-names></string-name>, <string-name><surname>Mousavinejad</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Anamag</surname><given-names>F.T.</given-names></string-name>, <string-name><surname>Dinger</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Taheri</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ghafouri-Fard</surname><given-names>S.</given-names></string-name></person-group><article-title>Emerging role of non-coding RNAs in response of cancer cells to radiotherapy</article-title>. <source>Pathol. Res. Pract.</source><year>2021</year>; <volume>218</volume>:<fpage>153327</fpage>.<pub-id pub-id-type="pmid">33422780</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cui</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>D.L.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L.W.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.W.</given-names></string-name></person-group><article-title>Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance</article-title>. <source>Mol. Cancer</source>. <year>2020</year>; <volume>19</volume>:<fpage>58</fpage>.<pub-id pub-id-type="pmid">32171304</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grimes</surname><given-names>D.R.</given-names></string-name></person-group><article-title>Limitations of the radiosensitivity index as a direct prognostic marker</article-title>. <source>Lancet Oncol.</source><year>2022</year>; <volume>23</volume>:<fpage>1352</fpage>–<lpage>1353</lpage>.<pub-id pub-id-type="pmid">36328006</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sondka</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Bamford</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Ward</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Dunham</surname><given-names>I.</given-names></string-name>, <string-name><surname>Forbes</surname><given-names>S.A.</given-names></string-name></person-group><article-title>The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers</article-title>. <source>Nat. Rev. Cancer</source>. <year>2018</year>; <volume>18</volume>:<fpage>696</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">30293088</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>Z.H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>G.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D.K.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>R.Q.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>TCF19 contributes to cell proliferation of non-small cell lung cancer by inhibiting FOXO1</article-title>. <source>Cell Biol. Int.</source><year>2019</year>; <volume>43</volume>:<fpage>1416</fpage>–<lpage>1424</lpage>.<pub-id pub-id-type="pmid">31141247</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gong</surname><given-names>C.</given-names></string-name>, <string-name><surname>Li</surname><given-names>W.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>L.W.</given-names></string-name></person-group><article-title>AKBA inhibits radiotherapy resistance in lung cancer by inhibiting maspin methylation and regulating the AKT/FOXO1/p21 axis</article-title>. <source>J. Radiat. Res.</source><year>2022</year>; <volume>64</volume>:<fpage>33</fpage>–<lpage>43</lpage>.</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>W.</given-names></string-name>, <string-name><surname>He</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>W.</given-names></string-name></person-group><article-title>Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2</article-title>. <source>Int. J. Clin. Exp. Med.</source><year>2015</year>; <volume>8</volume>:<fpage>9142</fpage>.<pub-id pub-id-type="pmid">26309570</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id>
    <journal-id journal-id-type="publisher-id">narcancer</journal-id>
    <journal-title-group>
      <journal-title>NAR Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2632-8674</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10894039</article-id>
    <article-id pub-id-type="doi">10.1093/narcan/zcae008</article-id>
    <article-id pub-id-type="publisher-id">zcae008</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00030</subject>
        <subject>AcademicSubjects/SCI00980</subject>
        <subject>AcademicSubjects/SCI01060</subject>
        <subject>AcademicSubjects/SCI01140</subject>
        <subject>AcademicSubjects/SCI01180</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Cancer Data Resource</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>dbCRAF: a curated knowledgebase for regulation of radiation response in human cancer</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Jie</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Jing</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jin</surname>
          <given-names>Fangfang</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Qian</given-names>
        </name>
        <aff><institution>School of Environmental Science and Optoelectronic Technology, University of Science and Technology of China</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230026</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6107-6071</contrib-id>
        <name>
          <surname>Zhao</surname>
          <given-names>Guoping</given-names>
        </name>
        <aff><institution>Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230031</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Lijun</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230031</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Li</surname>
          <given-names>Xiaoyan</given-names>
        </name>
        <!--lixiaoyan@ahu.edu.cn-->
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3024-1705</contrib-id>
        <name>
          <surname>Xia</surname>
          <given-names>Junfeng</given-names>
        </name>
        <!--jfxia@ahu.edu.cn-->
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Cheng</surname>
          <given-names>Na</given-names>
        </name>
        <!--chengna@ahmu.edu.cn-->
        <aff><institution>School of Biomedical Engineering, Anhui Medical University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230032</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 15856916675; Email: <email>chengna@ahmu.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Junfeng Xia. Tel: +86 13966677630; Email: <email>jfxia@ahu.edu.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Xiaoyan Li. Tel: +86 13211738021; Email: <email>lixiaoyan@ahu.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-02-24">
      <day>24</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>24</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <volume>6</volume>
    <issue>1</issue>
    <elocation-id>zcae008</elocation-id>
    <history>
      <date date-type="accepted">
        <day>15</day>
        <month>2</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>10</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>9</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of NAR Cancer.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="zcae008.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Radiation therapy (RT) is one of the primary treatment modalities of cancer, with 40–60% of cancer patients benefiting from RT during their treatment course. The intrinsic radiosensitivity or acquired radioresistance of tumor cells would affect the response to RT and clinical outcomes in patients. Thus, mining the regulatory mechanisms in tumor radiosensitivity or radioresistance that have been verified by biological experiments and computational analysis methods will enhance the overall understanding of RT. Here, we describe a comprehensive database dbCRAF (<ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>) to document and annotate the factors (1,677 genes, 49 proteins and 612 radiosensitizers) linked with radiation response, including radiosensitivity, radioresistance in cancer cells and prognosis in cancer patients receiving RT. On the one hand, dbCRAF enables researchers to directly access knowledge for regulation of radiation response in human cancer buried in the vast literature. On the other hand, dbCRAF provides four flexible modules to analyze and visualize the functional relationship between these factors and clinical outcome, KEGG pathway and target genes. In conclusion, dbCRAF serves as a valuable resource for elucidating the regulatory mechanisms of radiation response in human cancers as well as for the improvement of RT options.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="zcae008figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>11835014</award-id>
        <award-id>U22A2038</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Anhui Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003995</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2208085QF193</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Fund for Excellent Young Scholars</institution>
            <institution-id institution-id-type="DOI">10.13039/100014717</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>12122510</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="9"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>As an intricate disease, cancer has greatly reduced human life expectancy worldwide (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). Radiation therapy (RT) is one of the prominent modalities for treating intricate diseases, and it can be used alone or in combination with other treatments to cure tumors and relieve tumor-related symptoms in cancer patients (<xref rid="B3" ref-type="bibr">3</xref>). However, the effects of RT are not specific to tumor cells and may cause side effects or toxicity to surrounding exposed organs and tissues (e.g. RT injury, secondary cancer) (<xref rid="B3" ref-type="bibr">3–5</xref>). Therefore, it is important to examine the molecular mechanism of radiation response that enhances tumor killing while reducing toxicity to surrounding normal tissues, which can ensure better therapeutic outcomes and provide meaningful improvement for cancer patients (<xref rid="B6" ref-type="bibr">6–8</xref>).</p>
    <p>Many researchers have dedicated their efforts to studying the molecular mechanisms of radiosensitivity, radioresistance in human tumor cell lines or prognosis in cancer patients receiving RT, but these valuable findings are scattered across multiple sources (<xref rid="B9" ref-type="bibr">9–11</xref>). To be specific, emerging evidence in the literature has connected more coding genes and various types of non-coding RNAs (ncRNAs) like microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) to radioresistance and radiosensitivity in human cancers. For example, Han <italic toggle="yes">et al.</italic> demonstrated that down-regulation of <italic toggle="yes">PVT1</italic> inhibits radioresistance in nasopharyngeal carcinoma cells (<xref rid="B12" ref-type="bibr">12</xref>). Wang et al. found that circ_0067835 knockdown suppresses colorectal cancer (CRC) progression and strengthens CRC cell radiosensitivity (<xref rid="B13" ref-type="bibr">13</xref>). Additionally, Wen <italic toggle="yes">et al.</italic> constructed the dbCRSR database, which contains 395 coding genes, 119 miRNAs and 306 chemical compounds that can modulate radiosensitivity (<xref rid="B14" ref-type="bibr">14</xref>). Moreover, with the development of sequencing technology, there has been extensive literature using computational analysis methods to elucidate the complex relationship between genes and cancer prognosis with RT (<xref rid="B15" ref-type="bibr">15–19</xref>). These findings also provide valuable insights for improving the clinical outcomes of RT. To sum up, the lack of an effective collection of these scattered data makes it difficult to obtain an overarching understanding of prior research on the molecular mechanisms of radiation response, thus hampering the further progress of RT treatment.</p>
    <p>To meet these needs, we developed an informative and functional database (dbCRAF, <ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>), which contains various factors (1,677 genes, 612 radiosensitizers and 49 proteins) associated with radiosensitivity, radioresistance in cancer cells and prognosis in cancer patients receiving RT. In addition, we collated miRNA-target, lncRNA-target, circRNA-target and drug-target interactions for ncRNAs and radiosensitizers associated with radiation response, allowing users to construct radiation response interaction networks. Furthermore, four analytics modules were designed to enable users to extract key factors or potential modulators affecting radiation response based on the collected data. In brief, dbCRAF aspires to be a one-stop online service for integrating and analyzing valuable information on cellular radiation response.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <p>This part introduces data collection and curation, interaction data processing, data analysis and visualization, and database design and web interface implementation for the dbCRAF database.</p>
    <sec id="SEC2-1">
      <title>Data collection and curation</title>
      <p>To conduct a systematic review of the literature, we first searched PubMed articles published between January 2000 to February 2022 using a list of keywords (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>) related to radiosensitivity, radioresistance and RT prognosis prediction. Second, we performed full-text screening to assess the eligibility of papers and extracted key information from the relevant articles using PubTator (<xref rid="B20" ref-type="bibr">20</xref>), including publication information, the factor (genes, proteins, radiosensitizers) that could regulate radiation response, cancer type, the regulation mode of each factor, gene expression fold change, the cytotoxicity of radiosensitizers, the cell line name, the type of model organism, the type of ray, the cancer tissue source, sample size, collection time, the type of radiotherapy and survival endpoint. Notably, we defined each evidence that linked a factor to radiation response in cancer as an association. Third, to guarantee consistent names for all obtained factors and related cancers, we unified the gene names using the gene symbol-alias conversion table from the HGNC database (2022.4.12 version) (<xref rid="B21" ref-type="bibr">21</xref>), and radiosensitizer using ‘Generic Name’ from the DrugBank database (<xref rid="B22" ref-type="bibr">22</xref>). Fourth, we harmonized cancer names with disease terms in the MeSH database (2022.8.8 version) according to the occurrence location of the tumor (<xref rid="B23" ref-type="bibr">23</xref>). Fifth, we retained the original content of the type of RT, cancer tissue source, the type of ray and survival endpoint due to the presence of multiple descriptions in many publications. This decision enables the database to provide a more comprehensive representation of the data. Lastly, we added the subcellular location annotation from the GeneCards database, exploring the relationship between different subcellular structures and gene products related to radiation response (<xref rid="B24" ref-type="bibr">24</xref>).</p>
      <p>All the above information has been processed using python or R scripts, and manually verified by at least two individuals to ensure its accuracy. The scripts employed for processing could be downloaded in dbCRAF.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Interaction data processing</title>
      <p>To enable users to mine more information based on the associations collected in dbCRAF and to comprehend the mechanisms underlying radiation response regulation, we gathered four kinds of interaction data and target genes of miRNAs, lncRNAs, circRNAs, and radiosensitizers related to radiation response, as shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>. We first collected the miRNA-target interactions of Homo sapiens with the support type of ‘Functional miRNA-target interactions’ from the miRTarBase database (<xref rid="B25" ref-type="bibr">25</xref>). Then, we obtained the lncRNA-target interactions in human that were confirmed by low-throughput methods such as RT-qPCR and western blot from LncRNA2Target database (<xref rid="B26" ref-type="bibr">26</xref>). Next, we organized the intersection of potential circRNA-target interactions from the CircInteractome (<xref rid="B27" ref-type="bibr">27</xref>) and Circbank (<xref rid="B28" ref-type="bibr">28</xref>) databases to improve confidence of these results derived from related predictive tools. Moreover, radiosensitizer (drug)–target interactions were retrieved from the DrugBank, PharmGKB (<xref rid="B29" ref-type="bibr">29</xref>) and CMap (<xref rid="B30" ref-type="bibr">30</xref>) databases. Finally, we also integrated protein-protein interaction (PPI) data for the target genes and the genes recorded in dbCRAF based on the STRING database (<xref rid="B31" ref-type="bibr">31</xref>) to infer the overall regulatory network.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Data analysis and visualization</title>
      <p>To further explore the association data and four kinds of interaction data, we constructed four analysis blocks equipped with visual aids such as Word Cloud graphs, Kaplan–Meier survival analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (<xref rid="B32" ref-type="bibr">32</xref>) and interaction network visualization. First, Word Cloud allows users to count and visualize the associations between factors and cancer recorded in dbCRAF. The size of each factor's representation in the Word Cloud is proportional to the number of associations it has. This visual representation helps users identify factors that have a higher number of associations. Second, we collected the RNA-seq and clinical data from the Cancer Genome Atlas (TCGA) database (<xref rid="B33" ref-type="bibr">33</xref>), and investigated whether the expression levels of miRNAs or mRNAs recorded in dbCRAF affected the clinical prognosis of samples receiving RT at different tumor stages (stages I–IV) in one or more types of cancer. The results are presented using Kaplan-Meier survival curves, enabling users to assess the impact of these factors on patient outcomes. Third, KEGG pathway enrichment analysis supports users to annotate genes related to radiation response according to the type of pathway involved, and the results are presented in the form of bubble chart. This visualization helps users understand the functional roles of the identified factors by displaying enriched pathways. Finally, interaction network visualization enables users to describe the interaction relationships of factors in dbCRAF, thus facilitating the screening of key genes and potential modulators of radiation response.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Database design and web interface implementation</title>
      <p>The dbCRAF website was developed using Apache Tomcat Server (<ext-link xlink:href="http://tomcat.apache.org" ext-link-type="uri">http://tomcat.apache.org</ext-link>), Flask (<ext-link xlink:href="https://pypi.org/project/Flask" ext-link-type="uri">https://pypi.org/project/Flask</ext-link>) and MySQL (<ext-link xlink:href="http://www.mysql.org" ext-link-type="uri">http://www.mysql.org</ext-link>). We used Python 3.10 for server-side scripting to provide query and computation support in the backend of the database, and used HTML5, CSS3, JQuery (version 1.12.4), AJAX, ECharts (<ext-link xlink:href="https://echarts.apache.org" ext-link-type="uri">https://echarts.apache.org</ext-link>), dataTables (<ext-link xlink:href="https://datatables.net" ext-link-type="uri">https://datatables.net</ext-link>) and BootStrap (<ext-link xlink:href="https://getbootstrap.com" ext-link-type="uri">https://getbootstrap.com</ext-link>) frameworks to develop a user-friendly interactive web interface. Additionally, we employed various Python packages for the implementation of the ‘Analysis’ interface, including lifelines (version 0.27.0), gseapy (version 0.10.8), matplotlib (version 3.5.2), numpy (version 1.22.4), pandas (version 1.4.2) and matplotlib (version 3.5.2). We recommend visiting dbCRAF by a web browser such as Google Chrome, Microsoft Edge or Firefox.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Database content summary</title>
      <p>After excluding duplicate articles with the same PubMed ID or title, we retained &gt;10,000 records. Particularly, we classifies those literature about exploring the molecular mechanism of radiosensitivity and radioresistance through over-expression or knock-down assays as ‘Experiment’, and labels those about predicting radiation response and RT prognosis of cancer patients through computational analysis as ‘Prediction’. We then screened the full-text records to assess their relevance and extracted key information. dbCRAF currently contains 4,448 association entries between factors and cancer from 2,670 publications and it covers 1,677 genes, 612 radiosensitizers, and 49 proteins linked with 30 types of cancer.</p>
      <p>In comparison to the dbCRSR database, the dbCRAF database encompassed literature with a longer time span, as indicated in Table <xref rid="tbl1" ref-type="table">1</xref>. Additionally, dbCRAF provided information on multiple mechanisms of radiation response, resulting in a greater number of associations between factors and radiation response in cancer being recorded. Moreover, dbCRAF included descriptions of the various modes through which each factor modulated the radiation response in cancer. These modes included the addition of radiosensitizers, occurrence of gene mutation, changes in gene expression level, gene methylation status or protein expression. In summary, the information contained in dbCRAF is more comprehensive.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>The statistic and comparison of dbCRSR and dbCRAF databases</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Term</th>
              <th rowspan="1" colspan="1">dbCRSR</th>
              <th rowspan="1" colspan="1">dbCRAF</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Database function</td>
              <td rowspan="1" colspan="1">Download, search</td>
              <td rowspan="1" colspan="1">Download, search, analysis</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication source</td>
              <td rowspan="1" colspan="1">PubMed</td>
              <td rowspan="1" colspan="1">PubMed</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication date</td>
              <td rowspan="1" colspan="1">January 2008–October 2017</td>
              <td rowspan="1" colspan="1">January 2000–February 2022</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication number</td>
              <td rowspan="1" colspan="1">1,072</td>
              <td rowspan="1" colspan="1">2,670</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Association number</td>
              <td rowspan="1" colspan="1">1,132</td>
              <td rowspan="1" colspan="1">4,448</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Mechanism</td>
              <td rowspan="1" colspan="1">Experiment (RS<sup>a</sup>)</td>
              <td rowspan="1" colspan="1">Experiment (RS/RR<sup>b</sup>), prediction</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Factor type</td>
              <td rowspan="1" colspan="1">mRNA (395), miRNA (119), compound (306)</td>
              <td rowspan="1" colspan="1">Gene (1,677), protein (49), radiosensitizer (612)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T1TFN1">
            <p><sup>a</sup>Radiosensitivity.</p>
          </fn>
          <fn id="T1TFN2">
            <p><sup>b</sup>Radioresistance.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>In addition, we made three findings by analyzing the 4,448 associations recorded in dbCRAF. First, the number of studies that focused on molecular mechanisms of radiation response showed an increasing trend year by year (Figure <xref rid="F1" ref-type="fig">1A</xref>). This indicates the growing interest in understanding the molecular mechanisms of radiation response and its potential applications in cancer treatment. Meanwhile, recent studies published since 2018 have integrated the analysis of large genomic or transcriptome datasets with biological experiments to efficiently screen and verify genes of interest. This approach eliminated the limitations imposed by prior knowledge or assumptions and provided stronger evidence for identifying potential new associations between factors and cancer. Second, more than half of the associations were related to head and neck neoplasms, lung neoplasms, and breast neoplasms (Figure <xref rid="F1" ref-type="fig">1B</xref>), which might be due to their higher incidence or the wider use of RT options and thus leading to more relevant studies (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B34" ref-type="bibr">34–36</xref>). Third, the largest number of factors involved in regulating cancer radiation response were genes, followed by radiosensitizers (Figure <xref rid="F1" ref-type="fig">1C</xref>). Lastly, we separately counted the five categories of genes and found that in addition to protein-coding genes, there has been an increasing amount of ncRNAs documented in the radiation response-related literature (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Summary of dbCRAF contents. (<bold>A</bold>) Statistics of publication information. (<bold>B</bold>) Statistics of association data with each cancer type. (<bold>C</bold>) Statistics of association data with each kind of factor.</p>
        </caption>
        <graphic xlink:href="zcae008fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Hot protein-coding gene and enriched pathways</title>
      <p>After counting 2,658 associations between coding gene and cancer, we found a total of 1,308 coding genes. Among them, <italic toggle="yes">HIF1A</italic>, <italic toggle="yes">EGFR</italic>, and <italic toggle="yes">ATM</italic> were the most extensively studied coding genes, and their expression levels could influence the response of multiple tumors to radiation (Figure <xref rid="F2" ref-type="fig">2A</xref>). Next, we grouped all coding genes (793 versus 666) collected in ‘Experiment’ and ‘Prediction’ articles respectively, and obtained 151 genes shared between them (Figure <xref rid="F2" ref-type="fig">2B</xref>). This indicates that both biological experiments and computational methods have identified these 151 genes as potential genetic biomarkers for prognosis, radiosensitivity or radioresistance in human cancer. This finding suggests the possibility of optimizing RT effects based on a patient's genomic profiles and intrinsic radiosensitivity (<xref rid="B39" ref-type="bibr">39</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Overview of protein-coding gene-cancer associations. (<bold>A</bold>) Word cloud of all protein-coding genes, where there is more literature evidence for genes are displayed using a larger font size. (<bold>B</bold>) Number of coding genes derived from Experiment or Prediction publications. (<bold>C</bold>) The top 20 KEGG enrichment pathways of coding genes with experimental evidence (793 genes) or only computational analysis results (515 genes).</p>
        </caption>
        <graphic xlink:href="zcae008fig2" position="float"/>
      </fig>
      <p>Additionally, we analyzed 515 coding genes related to cancer prognosis identified in the ‘Prediction’ articles but not in the ‘Experiment’ articles to uncover more potential genetic biomarkers. Specifically, we performed the KEGG pathway enrichment analysis on the two groups of coding genes (793 versus 515) with or without experimental evidence of regulating radiation response. The results showed that four pathways were the same in both groups of genes, including IL-17 signaling pathway, neurodegeneration-multiple diseases pathways, pathways in cancer, and proteoglycans in cancer (Figure <xref rid="F2" ref-type="fig">2C</xref>). In summary, 137 of the 515 coding genes are involved in one or more of these four pathways (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>), and it is likely that they regulate radiosensitivity, radioresistance or prognosis in cancer through their involvement in these functional pathways.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Noncoding RNA, radiosensitizer and their target genes analysis</title>
      <p>Non-coding RNAs and radiosensitizers typically exert regulatory function in radiation response via interacting with target genes. Therefore, we collected and analyzed interaction data of ncRNAs and radiosensitizers related to radiation response from various databases (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). First, we counted the most studied miRNAs, lncRNAs and radiosensitizers based on association data documented in dbCRAF. As shown in Figure <xref rid="F3" ref-type="fig">3A</xref>, the top four ncRNAs and radiosensitizers were all involved in modulating radiation response in one or more cancers. Notably, there were only 31 associations between circRNA and cancer, making it difficult to sort circRNAs according to the study frequency. Second, we integrated all target genes and interaction data of ncRNAs and radiosensitizers linked with radiation response, including miRNA-target interactions, lncRNA-target interactions, circRNA–target interactions and radiosensitizer-target interactions. Interestingly, almost 25% of the target genes have been documented to be associated with radiation response (Figure <xref rid="F3" ref-type="fig">3B</xref>). Third, we counted the top 20 target genes that appeared most frequently in the interaction data and collected evidence for their regulation of radiation response. We hypothesized that target genes that appear more frequently in the interaction data are more likely to regulate radiosensitivity or radioresistance. Coincidentally, 19 of the top 20 target genes have been experimentally confirmed to regulate the radiation response (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>), with only the <italic toggle="yes">FOXO1</italic> gene lacking study evidence.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Statistics related to non-coding RNAs, radiosensitizers and their target interactions. (<bold>A</bold>) Statistics of the associations about top four miRNAs, lncRNAs and radiosensitizers, where more frequent associations are displayed using a thicker line. (<bold>B</bold>) Venn diagram of genes recorded in dbCRAF and all target genes. (<bold>C</bold>) Sankey diagram of FOXO1–miRNA–cancer associations.</p>
        </caption>
        <graphic xlink:href="zcae008fig3" position="float"/>
      </fig>
      <p>Therefore, we combined miRNA-target (<italic toggle="yes">FOXO1</italic>) interactions and relevant associations between miRNA and cancer recorded in dbCRAF to map <italic toggle="yes">FOXO1</italic>-miRNA-cancer associations. The results showed that <italic toggle="yes">FOXO1</italic> may be associated with radiation responses in lung neoplasms and head and neck neoplasms (Figure <xref rid="F3" ref-type="fig">3C</xref>). Although there is no direct evidence suggesting that <italic toggle="yes">FOXO1</italic> regulates the radiation response of cancer cells, <italic toggle="yes">FOXO1</italic> is still an important factor in cancer processes based on its inclusion in the oncogene and tumor suppressor gene list from the Cancer Gene Census project (<xref rid="B40" ref-type="bibr">40</xref>). Additionally, Zhou <italic toggle="yes">et al.</italic> found that <italic toggle="yes">TCF19</italic> could promote cell proliferation in non‐small cell lung cancer by inhibiting <italic toggle="yes">FOXO1</italic> (<xref rid="B41" ref-type="bibr">41</xref>). Gong <italic toggle="yes">et al.</italic> also showed that the <italic toggle="yes">AKBA</italic> gene inhibited radioresistance in lung cancer through the regulation of the <italic toggle="yes">AKT</italic>/<italic toggle="yes">FOXO1</italic>/<italic toggle="yes">p21</italic> axis (<xref rid="B42" ref-type="bibr">42</xref>). These findings support our conclusion that <italic toggle="yes">FOXO1</italic> may be closely related to the occurrence and prognosis of RT in lung cancer.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Key dbCRAF modules and user cases</title>
      <p>dbCRAF provides a comprehensive collection of high-quality data, including association data between factors and radiation response in cancer as well as interaction data between factors and target genes. All data are freely available through the Download module, and users can browse and analyze the data using the Data-Matrix, Search, and Analysis modules on the dbCRAF website (<ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>), as shown in Figure <xref rid="F4" ref-type="fig">4</xref>.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Schematic of dbCRAF.</p>
        </caption>
        <graphic xlink:href="zcae008fig4" position="float"/>
      </fig>
      <p>The ‘Data-Matrix’ page is an interactive and digitized table organized by factors (rows) associated with radiation response and cancer types (columns), allowing users to quickly navigate all association entries.</p>
      <p>For the Search page, dbCRAF provides user-friendly search options supporting automatic retrieval of association data recorded in dbCRAF under multiple cancer types. In addition, users can query the related data with different evidence in three ways: ‘By All’, ‘By Experiment’ and ‘By Prediction’. Furthermore, users can click the corresponding entry to view all detailed information, such as key sentences and biological experiment settings.</p>
      <p>On the Analysis page, dbCRAF supports four practical analysis functions to answer common biological questions. Users can perform word cloud, KEGG pathway enrichment analysis, and interaction network visualization using a list of factors related to radiation response along with their interaction data. Kaplan-Meier survival analysis is implemented with the miRNA-seq, mRNA-seq and clinical data of cancer patients treated with RT in the TCGA database.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>To the best of our knowledge, dbCRAF is the first database to furnish association data between factor and human cancer related to multiple radiation response regulatory mechanisms, including radiosensitivity, radioresistance, and prognosis of RT in cancer patients. At the same time, we gathered the interaction data concerning ncRNAs and radiosensitizers linked to radiation response. On top of that, dbCRAF allows users to analyze the above information, and provides an all-in-one service for the retrieval, analysis, and visualization of human cancer radiation response factors related to human cancer.</p>
    <p>For this study, we ran statistical analyses of association data retrieved from the PubMed literature, interaction data and target genes derived from multiple databases, respectively, to provide more guidance for researchers. Moreover, we found that out of the 666 coding genes related to tumor RT prognosis, a total of 151 genes had been validated by over-expression or knock-down assays. These assays have demonstrated their potential influence on the radiosensitivity or radioresistance of cancer cell lines. Therefore, it is essential to perform biological experiments on the remaining 515 genes to investigate their regulatory mechanism of response to radiation in human cancer cells. Additionally, regarding the data of miRNA-target interactions, we observed that hsa-miR-195–5p interacted with <italic toggle="yes">BCL2</italic>, the target gene with the most interaction data (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>). Interestingly, earlier studies revealed that hsa-miR-195-5p could enhance the radiosensitivity of breast cancer cells by repressing the expression of <italic toggle="yes">BCL2</italic> (<xref rid="B43" ref-type="bibr">43</xref>). Consequently, it is feasible to discover more potential biomarkers of radiation response by utilizing both information including the associations between factor and cancer in dbCRAF and corresponding interactions between factor and target gene.</p>
    <p>This work also has several limitations that require further exploration. On the one hand, the current database lacks information on radiation toxicity, the change of radiosensitivity, treatment options and machines. It is necessary to explore and include this additional information from relevant literature or databases in the future to enhance the understanding of radiation response. On the other hand, we observed that more than half of the associations are linked to head and neck neoplasms, lung neoplasms and breast neoplasms. This disproportionate distribution may introduce bias in the database and the biological information it contains. To address this issue, we are considering implementing mechanisms such as weighting, where cancer types with fewer associations are given greater weight when inferring potential associations between genes and radiation response in cancer. Furthermore, it is crucial to supplement associations of cancer types with limited data by incorporating information from additional sources like Web of Science and Scopus. These efforts will contribute to a more comprehensive representation of radiation response and help mitigate potential bias across various types of cancer.</p>
    <p>In conclusion, with the collated data and the implementation of four online analysis tools, dbCRAF is not only an integrated resource, but also a web server for mining the potential molecular mechanisms of radiation response. The data and the functions of dbCRAF may be provide new perspectives on the development of RT therapeutics for human cancer.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>zcae008_supplemental_file</label>
      <media xlink:href="zcae008_supplemental_file.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>The authors acknowledge the High-performance Computing Platform of Anhui University for providing computing resources. We would like to thank the Xia laboratory members for their participation in the data collection in this work.</p>
    <p><italic toggle="yes">Author contributions</italic>: J. Liu: Data curation, Methodology, Writing-original draft. J. Li.: Database design, Writing - original draft. F. Jin: Database design. Q. Li: Methodology. G. Zhao: Writing-review &amp; editing. L. Wu: Writing-review &amp; editing. X. Li: Supervision, Writing-review &amp; editing. J. Xia: Conceptualization, Supervision, Writing-review &amp; editing. N. Cheng: Conceptualization, Supervision, Writing-review &amp; editing.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>No new data were generated or analysed in support of this research.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcae008#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Cancer Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Natural Science Foundation of China [11835014, U22A2038]; Natural Science Foundation of Anhui Province [2208085QF193]; National Science Fund for Excellent Young Scholars [12122510].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sung</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J.</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Laversanne</surname><given-names>M.</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bray</surname><given-names>F.</given-names></string-name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin.</source><year>2021</year>; <volume>71</volume>:<fpage>209</fpage>–<lpage>249</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bray</surname><given-names>F.</given-names></string-name>, <string-name><surname>Laversanne</surname><given-names>M.</given-names></string-name>, <string-name><surname>Weiderpass</surname><given-names>E.</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I.</given-names></string-name></person-group><article-title>The ever-increasing importance of cancer as a leading cause of premature death worldwide</article-title>. <source>Cancer-Am Cancer Soc.</source><year>2021</year>; <volume>127</volume>:<fpage>3029</fpage>–<lpage>3030</lpage>.</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>K.</given-names></string-name>, <string-name><surname>Tepper</surname><given-names>J.E.</given-names></string-name></person-group><article-title>Radiation therapy-associated toxicity: etiology, management, and prevention</article-title>. <source>CA Cancer J Clin.</source><year>2021</year>; <volume>71</volume>:<fpage>437</fpage>–<lpage>454</lpage>.<pub-id pub-id-type="pmid">34255347</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bentzen</surname><given-names>S.M.</given-names></string-name></person-group><article-title>Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology</article-title>. <source>Nat. Rev. Cancer</source>. <year>2006</year>; <volume>6</volume>:<fpage>702</fpage>–<lpage>713</lpage>.<pub-id pub-id-type="pmid">16929324</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quon</surname><given-names>H.</given-names></string-name>, <string-name><surname>McNutt</surname><given-names>T.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bowers</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Lakshminarayanan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Han</surname><given-names>P.J.</given-names></string-name>, <string-name><surname>Hui</surname><given-names>X.</given-names></string-name>, <string-name><surname>Moore</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Needs and challenges for radiation oncology in the era of precision medicine</article-title>. <source>Int. J Radiat Oncol.</source><year>2019</year>; <volume>103</volume>:<fpage>809</fpage>–<lpage>817</lpage>.</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bernier</surname><given-names>J.</given-names></string-name></person-group><article-title>Precision medicine for early breast cancer radiotherapy: opening up new horizons?</article-title>. <source>Crit. Rev. Oncol. Hemat.</source><year>2017</year>; <volume>113</volume>:<fpage>79</fpage>–<lpage>82</lpage>.</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>H.H.W.</given-names></string-name>, <string-name><surname>Kuo</surname><given-names>M.T.</given-names></string-name></person-group><article-title>Improving radiotherapy in cancer treatment: promises and challenges</article-title>. <source>Oncotarget</source>. <year>2017</year>; <volume>8</volume>:<fpage>62742</fpage>–<lpage>62758</lpage>.<pub-id pub-id-type="pmid">28977985</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marks</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Yorke</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ten Haken</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Constine</surname><given-names>L.S.</given-names></string-name>, <string-name><surname>Eisbruch</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bentzen</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Nam</surname><given-names>J.</given-names></string-name>, <string-name><surname>Deasy</surname><given-names>J.O.</given-names></string-name></person-group><article-title>Use of normal tissue complication probability models in the clinic</article-title>. <source>Int. J Radiat. Oncol.</source><year>2010</year>; <volume>76</volume>:<fpage>S10</fpage>–<lpage>S19</lpage>.</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Galeaz</surname><given-names>C.</given-names></string-name>, <string-name><surname>Totis</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bisio</surname><given-names>A.</given-names></string-name></person-group><article-title>Radiation resistance: a matter of transcription factors</article-title>. <source>Front. Oncol.</source><year>2021</year>; <volume>11</volume>:<fpage>662840</fpage>.<pub-id pub-id-type="pmid">34141616</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>F.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name></person-group><article-title>Radiation-induced cell death and its mechanisms</article-title>. <source>Health Phys.</source><year>2022</year>; <volume>123</volume>:<fpage>376</fpage>–<lpage>386</lpage>.<pub-id pub-id-type="pmid">36069830</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xi</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>D.H.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>An omics-to-omics joint knowledge association subtensor model for radiogenomics cross-modal modules from genomics and ultrasonic images of breast cancers</article-title>. <source>Comput. Biol. Med.</source><year>2023</year>; <volume>155</volume>:<fpage>106672</fpage>.<pub-id pub-id-type="pmid">36805226</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name></person-group><article-title>PVT1 mediates cell proliferation, apoptosis and radioresistance in nasopharyngeal carcinoma through regulating miR-515-5p/PIK3CA Axis</article-title>. <source>Cancer Manag. Res.</source><year>2020</year>; <volume>12</volume>:<fpage>10077</fpage>–<lpage>10090</lpage>.<pub-id pub-id-type="pmid">33116864</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>P.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y.M.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name></person-group><article-title>Circ_0067835 knockdown enhances the radiosensitivity of colorectal cancer by miR-296-5p/IGF1R axis</article-title>. <source>Oncotargets Ther.</source><year>2021</year>; <volume>14</volume>:<fpage>491</fpage>–<lpage>502</lpage>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wen</surname><given-names>P.B.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>X.B.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>B.</given-names></string-name>, <string-name><surname>Tao</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>G.P.</given-names></string-name></person-group><article-title>dbCRSR: a manually curated database for regulation of cancer radiosensitivity</article-title>. <source>Database-Oxford</source>. <year>2018</year>; <volume>2018</volume>:<fpage>bay049</fpage>.<pub-id pub-id-type="pmid">29860480</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Principe</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zapater-Latorre</surname><given-names>E.</given-names></string-name>, <string-name><surname>Arribas</surname><given-names>L.</given-names></string-name>, <string-name><surname>Garcia-Miragall</surname><given-names>E.</given-names></string-name>, <string-name><surname>Bagan</surname><given-names>J.</given-names></string-name></person-group><article-title>Salivary IL-8 as a putative predictive biomarker of radiotherapy response in head and neck cancer patients</article-title>. <source>Clin. Oral. Invest.</source><year>2022</year>; <volume>26</volume>:<fpage>437</fpage>–<lpage>448</lpage>.</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>L.</given-names></string-name>, <string-name><surname>Geng</surname><given-names>R.R.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y.F.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Z.X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S.B.</given-names></string-name></person-group><article-title>An 11-gene signature based on treatment responsiveness pedicts radiation therapy survival benefit among breast cancer patients</article-title>. <source>Front. Oncol.</source><year>2022</year>; <volume>11</volume>:<fpage>816053</fpage>.<pub-id pub-id-type="pmid">35071020</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Gu</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Z.Q.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>X.C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Q.Y.</given-names></string-name></person-group><article-title>A radioresponse-related lncRNA biomarker signature for risk classification and prognosis prediction in non-small-cell lung cancer</article-title>. <source>J. Oncol.</source><year>2021</year>; <volume>2021</volume>:<fpage>4338838</fpage>.<pub-id pub-id-type="pmid">34594376</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>C.D.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name></person-group><article-title>RTPDB: a database providing associations between genetic variation or expression and cancer prognosis with radiotherapy-based treatment</article-title>. <source>Database</source>. <year>2018</year>; <volume>2018</volume>:<fpage>bay118</fpage>.<pub-id pub-id-type="pmid">30376049</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xi</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>X.G.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>A.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>Inferring subgroup-specific driver genes from heterogeneous cancer samples via subspace learning with subgroup indication</article-title>. <source>Bioinformatics</source>. <year>2020</year>; <volume>36</volume>:<fpage>1855</fpage>–<lpage>1863</lpage>.<pub-id pub-id-type="pmid">31626284</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Allot</surname><given-names>A.</given-names></string-name>, <string-name><surname>Leaman</surname><given-names>R.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Z.Y.</given-names></string-name></person-group><article-title>PubTator central: automated concept annotation for biomedical full text articles</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>W587</fpage>–<lpage>W593</lpage>.<pub-id pub-id-type="pmid">31114887</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tweedie</surname><given-names>S.</given-names></string-name>, <string-name><surname>Braschi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>T.E.M.</given-names></string-name>, <string-name><surname>Seal</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Yates</surname><given-names>B.</given-names></string-name>, <string-name><surname>Bruford</surname><given-names>E.A.</given-names></string-name></person-group><article-title>Genenames.org: the HGNC and VGNC resources in 2021</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D939</fpage>–<lpage>D946</lpage>.<pub-id pub-id-type="pmid">33152070</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lipscomb</surname><given-names>C.E.J.B.o.t.M.L.A.</given-names></string-name></person-group><article-title>Medical subject headings (MeSH)</article-title>. <source>Bull. Med. Libr. Assoc.</source><year>2000</year>; <volume>88</volume>:<fpage>265</fpage>–<lpage>266</lpage>.<pub-id pub-id-type="pmid">10928714</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Safran</surname><given-names>M.</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Twik</surname><given-names>M.</given-names></string-name>, <string-name><surname>BarShir</surname><given-names>R.</given-names></string-name>, <string-name><surname>Stein</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Dahary</surname><given-names>D.</given-names></string-name>, <string-name><surname>Fishilevich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lancet</surname><given-names>D</given-names></string-name></person-group><source>Practical Guide to Life Science Databases</source>. <year>2021</year>; <publisher-name>Springer</publisher-name><fpage>27</fpage>–<lpage>56</lpage>.</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y.C.D.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y.X.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>J.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.L.</given-names></string-name>, <string-name><surname>Wen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zuo</surname><given-names>H.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D222</fpage>–<lpage>D230</lpage>.<pub-id pub-id-type="pmid">34850920</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P.P.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>Q.H.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>W.Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>LncRNA2Target v2.0: a comprehensive database for target genes of lncRNAs in human and mouse</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D140</fpage>–<lpage>D144</lpage>.<pub-id pub-id-type="pmid">30380072</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dudekulay</surname><given-names>D.B.</given-names></string-name>, <string-name><surname>Panda</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Grammatikakis</surname><given-names>I.</given-names></string-name>, <string-name><surname>De</surname><given-names>S.</given-names></string-name>, <string-name><surname>Abdelmohsen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Gorospe</surname><given-names>M.</given-names></string-name></person-group><article-title>CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs</article-title>. <source>Rna Biol.</source><year>2016</year>; <volume>13</volume>:<fpage>34</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">26669964</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B.B.</given-names></string-name>, <string-name><surname>Ding</surname><given-names>X.M.</given-names></string-name></person-group><article-title>Circbank: a comprehensive database for circRNA with standard nomenclature</article-title>. <source>Rna Biol.</source><year>2019</year>; <volume>16</volume>:<fpage>899</fpage>–<lpage>905</lpage>.<pub-id pub-id-type="pmid">31023147</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whirl-Carrillo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huddart</surname><given-names>R.</given-names></string-name>, <string-name><surname>Gong</surname><given-names>L.</given-names></string-name>, <string-name><surname>Sangkuhl</surname><given-names>K.</given-names></string-name>, <string-name><surname>Thorn</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Whaley</surname><given-names>R.</given-names></string-name>, <string-name><surname>Klein</surname><given-names>T.E.</given-names></string-name></person-group><article-title>An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine</article-title>. <source>Clin. Pharmacol. Ther.</source><year>2021</year>; <volume>110</volume>:<fpage>563</fpage>–<lpage>572</lpage>.<pub-id pub-id-type="pmid">34216021</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X.D.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname><given-names>J.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szklarczyk</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gable</surname><given-names>A.L.</given-names></string-name>, <string-name><surname>Nastou</surname><given-names>K.C.</given-names></string-name>, <string-name><surname>Lyon</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kirsch</surname><given-names>R.</given-names></string-name>, <string-name><surname>Pyysalo</surname><given-names>S.</given-names></string-name>, <string-name><surname>Doncheva</surname><given-names>N.T.</given-names></string-name>, <string-name><surname>Legeay</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Bork</surname><given-names>P.</given-names></string-name></person-group><article-title>The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D605</fpage>–<lpage>D612</lpage>.<pub-id pub-id-type="pmid">33237311</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Goto</surname><given-names>S.</given-names></string-name></person-group><article-title>KEGG: Kyoto encyclopedia of genes and genomes</article-title>. <source>Nucleic Acids Res.</source><year>2000</year>; <volume>28</volume>:<fpage>27</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">10592173</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomczak</surname><given-names>K.</given-names></string-name>, <string-name><surname>Czerwińska</surname><given-names>P.</given-names></string-name>, <string-name><surname>Wiznerowicz</surname><given-names>M.</given-names></string-name></person-group><article-title>Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge</article-title>. <source>Contemp Oncol.</source><year>2015</year>; <volume>2015</volume>:<fpage>68</fpage>–<lpage>77</lpage>.</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chow</surname><given-names>L.Q.</given-names></string-name></person-group><article-title>Head and neck cancer</article-title>. <source>N. Engl. J Med.</source><year>2020</year>; <volume>382</volume>:<fpage>60</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">31893516</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lemjabbar-Alaoui</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hassan</surname><given-names>O.U.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.W.</given-names></string-name>, <string-name><surname>Buchanan</surname><given-names>P.</given-names></string-name></person-group><article-title>Lung cancer: biology and treatment options</article-title>. <source>Bba-Rev Cancer</source>. <year>2015</year>; <volume>1856</volume>:<fpage>189</fpage>–<lpage>210</lpage>.</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al-Mahmood</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sapiezynski</surname><given-names>J.</given-names></string-name>, <string-name><surname>Garbuzenko</surname><given-names>O.B.</given-names></string-name>, <string-name><surname>Minko</surname><given-names>T.</given-names></string-name></person-group><article-title>Metastatic and triple-negative breast cancer: challenges and treatment options</article-title>. <source>Drug Deliv. Transl. Re</source>. <year>2018</year>; <volume>8</volume>:<fpage>1483</fpage>–<lpage>1507</lpage>.</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ebahimzadeh</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shoorei</surname><given-names>H.</given-names></string-name>, <string-name><surname>Mousavinejad</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Anamag</surname><given-names>F.T.</given-names></string-name>, <string-name><surname>Dinger</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Taheri</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ghafouri-Fard</surname><given-names>S.</given-names></string-name></person-group><article-title>Emerging role of non-coding RNAs in response of cancer cells to radiotherapy</article-title>. <source>Pathol. Res. Pract.</source><year>2021</year>; <volume>218</volume>:<fpage>153327</fpage>.<pub-id pub-id-type="pmid">33422780</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cui</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>D.L.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L.W.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.W.</given-names></string-name></person-group><article-title>Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance</article-title>. <source>Mol. Cancer</source>. <year>2020</year>; <volume>19</volume>:<fpage>58</fpage>.<pub-id pub-id-type="pmid">32171304</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grimes</surname><given-names>D.R.</given-names></string-name></person-group><article-title>Limitations of the radiosensitivity index as a direct prognostic marker</article-title>. <source>Lancet Oncol.</source><year>2022</year>; <volume>23</volume>:<fpage>1352</fpage>–<lpage>1353</lpage>.<pub-id pub-id-type="pmid">36328006</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sondka</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Bamford</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Ward</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Dunham</surname><given-names>I.</given-names></string-name>, <string-name><surname>Forbes</surname><given-names>S.A.</given-names></string-name></person-group><article-title>The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers</article-title>. <source>Nat. Rev. Cancer</source>. <year>2018</year>; <volume>18</volume>:<fpage>696</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">30293088</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>Z.H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>G.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D.K.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>R.Q.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>TCF19 contributes to cell proliferation of non-small cell lung cancer by inhibiting FOXO1</article-title>. <source>Cell Biol. Int.</source><year>2019</year>; <volume>43</volume>:<fpage>1416</fpage>–<lpage>1424</lpage>.<pub-id pub-id-type="pmid">31141247</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gong</surname><given-names>C.</given-names></string-name>, <string-name><surname>Li</surname><given-names>W.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>L.W.</given-names></string-name></person-group><article-title>AKBA inhibits radiotherapy resistance in lung cancer by inhibiting maspin methylation and regulating the AKT/FOXO1/p21 axis</article-title>. <source>J. Radiat. Res.</source><year>2022</year>; <volume>64</volume>:<fpage>33</fpage>–<lpage>43</lpage>.</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>W.</given-names></string-name>, <string-name><surname>He</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>W.</given-names></string-name></person-group><article-title>Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2</article-title>. <source>Int. J. Clin. Exp. Med.</source><year>2015</year>; <volume>8</volume>:<fpage>9142</fpage>.<pub-id pub-id-type="pmid">26309570</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">NAR Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">NAR Cancer</journal-id>
    <journal-id journal-id-type="publisher-id">narcancer</journal-id>
    <journal-title-group>
      <journal-title>NAR Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2632-8674</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10894039</article-id>
    <article-id pub-id-type="doi">10.1093/narcan/zcae008</article-id>
    <article-id pub-id-type="publisher-id">zcae008</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00030</subject>
        <subject>AcademicSubjects/SCI00980</subject>
        <subject>AcademicSubjects/SCI01060</subject>
        <subject>AcademicSubjects/SCI01140</subject>
        <subject>AcademicSubjects/SCI01180</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Cancer Data Resource</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>dbCRAF: a curated knowledgebase for regulation of radiation response in human cancer</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Jie</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Jing</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jin</surname>
          <given-names>Fangfang</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Qian</given-names>
        </name>
        <aff><institution>School of Environmental Science and Optoelectronic Technology, University of Science and Technology of China</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230026</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6107-6071</contrib-id>
        <name>
          <surname>Zhao</surname>
          <given-names>Guoping</given-names>
        </name>
        <aff><institution>Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230031</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Lijun</given-names>
        </name>
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230031</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Li</surname>
          <given-names>Xiaoyan</given-names>
        </name>
        <!--lixiaoyan@ahu.edu.cn-->
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3024-1705</contrib-id>
        <name>
          <surname>Xia</surname>
          <given-names>Junfeng</given-names>
        </name>
        <!--jfxia@ahu.edu.cn-->
        <aff><institution>Key Laboratory of Intelligent Computing and Signal Processing of Ministry of Education and Information Materials and Intelligent Sensing Laboratory of Anhui Province, Institutes of Physical Science and Information Technology, Anhui University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230601</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Cheng</surname>
          <given-names>Na</given-names>
        </name>
        <!--chengna@ahmu.edu.cn-->
        <aff><institution>School of Biomedical Engineering, Anhui Medical University</institution>, <addr-line>Hefei</addr-line>, Anhui <addr-line>230032</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 15856916675; Email: <email>chengna@ahmu.edu.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Junfeng Xia. Tel: +86 13966677630; Email: <email>jfxia@ahu.edu.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Xiaoyan Li. Tel: +86 13211738021; Email: <email>lixiaoyan@ahu.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-02-24">
      <day>24</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>24</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <volume>6</volume>
    <issue>1</issue>
    <elocation-id>zcae008</elocation-id>
    <history>
      <date date-type="accepted">
        <day>15</day>
        <month>2</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>10</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>9</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of NAR Cancer.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="zcae008.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Radiation therapy (RT) is one of the primary treatment modalities of cancer, with 40–60% of cancer patients benefiting from RT during their treatment course. The intrinsic radiosensitivity or acquired radioresistance of tumor cells would affect the response to RT and clinical outcomes in patients. Thus, mining the regulatory mechanisms in tumor radiosensitivity or radioresistance that have been verified by biological experiments and computational analysis methods will enhance the overall understanding of RT. Here, we describe a comprehensive database dbCRAF (<ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>) to document and annotate the factors (1,677 genes, 49 proteins and 612 radiosensitizers) linked with radiation response, including radiosensitivity, radioresistance in cancer cells and prognosis in cancer patients receiving RT. On the one hand, dbCRAF enables researchers to directly access knowledge for regulation of radiation response in human cancer buried in the vast literature. On the other hand, dbCRAF provides four flexible modules to analyze and visualize the functional relationship between these factors and clinical outcome, KEGG pathway and target genes. In conclusion, dbCRAF serves as a valuable resource for elucidating the regulatory mechanisms of radiation response in human cancers as well as for the improvement of RT options.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="zcae008figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>11835014</award-id>
        <award-id>U22A2038</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Natural Science Foundation of Anhui Province</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003995</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2208085QF193</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Fund for Excellent Young Scholars</institution>
            <institution-id institution-id-type="DOI">10.13039/100014717</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>12122510</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="9"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>As an intricate disease, cancer has greatly reduced human life expectancy worldwide (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). Radiation therapy (RT) is one of the prominent modalities for treating intricate diseases, and it can be used alone or in combination with other treatments to cure tumors and relieve tumor-related symptoms in cancer patients (<xref rid="B3" ref-type="bibr">3</xref>). However, the effects of RT are not specific to tumor cells and may cause side effects or toxicity to surrounding exposed organs and tissues (e.g. RT injury, secondary cancer) (<xref rid="B3" ref-type="bibr">3–5</xref>). Therefore, it is important to examine the molecular mechanism of radiation response that enhances tumor killing while reducing toxicity to surrounding normal tissues, which can ensure better therapeutic outcomes and provide meaningful improvement for cancer patients (<xref rid="B6" ref-type="bibr">6–8</xref>).</p>
    <p>Many researchers have dedicated their efforts to studying the molecular mechanisms of radiosensitivity, radioresistance in human tumor cell lines or prognosis in cancer patients receiving RT, but these valuable findings are scattered across multiple sources (<xref rid="B9" ref-type="bibr">9–11</xref>). To be specific, emerging evidence in the literature has connected more coding genes and various types of non-coding RNAs (ncRNAs) like microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) to radioresistance and radiosensitivity in human cancers. For example, Han <italic toggle="yes">et al.</italic> demonstrated that down-regulation of <italic toggle="yes">PVT1</italic> inhibits radioresistance in nasopharyngeal carcinoma cells (<xref rid="B12" ref-type="bibr">12</xref>). Wang et al. found that circ_0067835 knockdown suppresses colorectal cancer (CRC) progression and strengthens CRC cell radiosensitivity (<xref rid="B13" ref-type="bibr">13</xref>). Additionally, Wen <italic toggle="yes">et al.</italic> constructed the dbCRSR database, which contains 395 coding genes, 119 miRNAs and 306 chemical compounds that can modulate radiosensitivity (<xref rid="B14" ref-type="bibr">14</xref>). Moreover, with the development of sequencing technology, there has been extensive literature using computational analysis methods to elucidate the complex relationship between genes and cancer prognosis with RT (<xref rid="B15" ref-type="bibr">15–19</xref>). These findings also provide valuable insights for improving the clinical outcomes of RT. To sum up, the lack of an effective collection of these scattered data makes it difficult to obtain an overarching understanding of prior research on the molecular mechanisms of radiation response, thus hampering the further progress of RT treatment.</p>
    <p>To meet these needs, we developed an informative and functional database (dbCRAF, <ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>), which contains various factors (1,677 genes, 612 radiosensitizers and 49 proteins) associated with radiosensitivity, radioresistance in cancer cells and prognosis in cancer patients receiving RT. In addition, we collated miRNA-target, lncRNA-target, circRNA-target and drug-target interactions for ncRNAs and radiosensitizers associated with radiation response, allowing users to construct radiation response interaction networks. Furthermore, four analytics modules were designed to enable users to extract key factors or potential modulators affecting radiation response based on the collected data. In brief, dbCRAF aspires to be a one-stop online service for integrating and analyzing valuable information on cellular radiation response.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <p>This part introduces data collection and curation, interaction data processing, data analysis and visualization, and database design and web interface implementation for the dbCRAF database.</p>
    <sec id="SEC2-1">
      <title>Data collection and curation</title>
      <p>To conduct a systematic review of the literature, we first searched PubMed articles published between January 2000 to February 2022 using a list of keywords (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>) related to radiosensitivity, radioresistance and RT prognosis prediction. Second, we performed full-text screening to assess the eligibility of papers and extracted key information from the relevant articles using PubTator (<xref rid="B20" ref-type="bibr">20</xref>), including publication information, the factor (genes, proteins, radiosensitizers) that could regulate radiation response, cancer type, the regulation mode of each factor, gene expression fold change, the cytotoxicity of radiosensitizers, the cell line name, the type of model organism, the type of ray, the cancer tissue source, sample size, collection time, the type of radiotherapy and survival endpoint. Notably, we defined each evidence that linked a factor to radiation response in cancer as an association. Third, to guarantee consistent names for all obtained factors and related cancers, we unified the gene names using the gene symbol-alias conversion table from the HGNC database (2022.4.12 version) (<xref rid="B21" ref-type="bibr">21</xref>), and radiosensitizer using ‘Generic Name’ from the DrugBank database (<xref rid="B22" ref-type="bibr">22</xref>). Fourth, we harmonized cancer names with disease terms in the MeSH database (2022.8.8 version) according to the occurrence location of the tumor (<xref rid="B23" ref-type="bibr">23</xref>). Fifth, we retained the original content of the type of RT, cancer tissue source, the type of ray and survival endpoint due to the presence of multiple descriptions in many publications. This decision enables the database to provide a more comprehensive representation of the data. Lastly, we added the subcellular location annotation from the GeneCards database, exploring the relationship between different subcellular structures and gene products related to radiation response (<xref rid="B24" ref-type="bibr">24</xref>).</p>
      <p>All the above information has been processed using python or R scripts, and manually verified by at least two individuals to ensure its accuracy. The scripts employed for processing could be downloaded in dbCRAF.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Interaction data processing</title>
      <p>To enable users to mine more information based on the associations collected in dbCRAF and to comprehend the mechanisms underlying radiation response regulation, we gathered four kinds of interaction data and target genes of miRNAs, lncRNAs, circRNAs, and radiosensitizers related to radiation response, as shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>. We first collected the miRNA-target interactions of Homo sapiens with the support type of ‘Functional miRNA-target interactions’ from the miRTarBase database (<xref rid="B25" ref-type="bibr">25</xref>). Then, we obtained the lncRNA-target interactions in human that were confirmed by low-throughput methods such as RT-qPCR and western blot from LncRNA2Target database (<xref rid="B26" ref-type="bibr">26</xref>). Next, we organized the intersection of potential circRNA-target interactions from the CircInteractome (<xref rid="B27" ref-type="bibr">27</xref>) and Circbank (<xref rid="B28" ref-type="bibr">28</xref>) databases to improve confidence of these results derived from related predictive tools. Moreover, radiosensitizer (drug)–target interactions were retrieved from the DrugBank, PharmGKB (<xref rid="B29" ref-type="bibr">29</xref>) and CMap (<xref rid="B30" ref-type="bibr">30</xref>) databases. Finally, we also integrated protein-protein interaction (PPI) data for the target genes and the genes recorded in dbCRAF based on the STRING database (<xref rid="B31" ref-type="bibr">31</xref>) to infer the overall regulatory network.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Data analysis and visualization</title>
      <p>To further explore the association data and four kinds of interaction data, we constructed four analysis blocks equipped with visual aids such as Word Cloud graphs, Kaplan–Meier survival analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (<xref rid="B32" ref-type="bibr">32</xref>) and interaction network visualization. First, Word Cloud allows users to count and visualize the associations between factors and cancer recorded in dbCRAF. The size of each factor's representation in the Word Cloud is proportional to the number of associations it has. This visual representation helps users identify factors that have a higher number of associations. Second, we collected the RNA-seq and clinical data from the Cancer Genome Atlas (TCGA) database (<xref rid="B33" ref-type="bibr">33</xref>), and investigated whether the expression levels of miRNAs or mRNAs recorded in dbCRAF affected the clinical prognosis of samples receiving RT at different tumor stages (stages I–IV) in one or more types of cancer. The results are presented using Kaplan-Meier survival curves, enabling users to assess the impact of these factors on patient outcomes. Third, KEGG pathway enrichment analysis supports users to annotate genes related to radiation response according to the type of pathway involved, and the results are presented in the form of bubble chart. This visualization helps users understand the functional roles of the identified factors by displaying enriched pathways. Finally, interaction network visualization enables users to describe the interaction relationships of factors in dbCRAF, thus facilitating the screening of key genes and potential modulators of radiation response.</p>
    </sec>
    <sec id="SEC2-4">
      <title>Database design and web interface implementation</title>
      <p>The dbCRAF website was developed using Apache Tomcat Server (<ext-link xlink:href="http://tomcat.apache.org" ext-link-type="uri">http://tomcat.apache.org</ext-link>), Flask (<ext-link xlink:href="https://pypi.org/project/Flask" ext-link-type="uri">https://pypi.org/project/Flask</ext-link>) and MySQL (<ext-link xlink:href="http://www.mysql.org" ext-link-type="uri">http://www.mysql.org</ext-link>). We used Python 3.10 for server-side scripting to provide query and computation support in the backend of the database, and used HTML5, CSS3, JQuery (version 1.12.4), AJAX, ECharts (<ext-link xlink:href="https://echarts.apache.org" ext-link-type="uri">https://echarts.apache.org</ext-link>), dataTables (<ext-link xlink:href="https://datatables.net" ext-link-type="uri">https://datatables.net</ext-link>) and BootStrap (<ext-link xlink:href="https://getbootstrap.com" ext-link-type="uri">https://getbootstrap.com</ext-link>) frameworks to develop a user-friendly interactive web interface. Additionally, we employed various Python packages for the implementation of the ‘Analysis’ interface, including lifelines (version 0.27.0), gseapy (version 0.10.8), matplotlib (version 3.5.2), numpy (version 1.22.4), pandas (version 1.4.2) and matplotlib (version 3.5.2). We recommend visiting dbCRAF by a web browser such as Google Chrome, Microsoft Edge or Firefox.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Database content summary</title>
      <p>After excluding duplicate articles with the same PubMed ID or title, we retained &gt;10,000 records. Particularly, we classifies those literature about exploring the molecular mechanism of radiosensitivity and radioresistance through over-expression or knock-down assays as ‘Experiment’, and labels those about predicting radiation response and RT prognosis of cancer patients through computational analysis as ‘Prediction’. We then screened the full-text records to assess their relevance and extracted key information. dbCRAF currently contains 4,448 association entries between factors and cancer from 2,670 publications and it covers 1,677 genes, 612 radiosensitizers, and 49 proteins linked with 30 types of cancer.</p>
      <p>In comparison to the dbCRSR database, the dbCRAF database encompassed literature with a longer time span, as indicated in Table <xref rid="tbl1" ref-type="table">1</xref>. Additionally, dbCRAF provided information on multiple mechanisms of radiation response, resulting in a greater number of associations between factors and radiation response in cancer being recorded. Moreover, dbCRAF included descriptions of the various modes through which each factor modulated the radiation response in cancer. These modes included the addition of radiosensitizers, occurrence of gene mutation, changes in gene expression level, gene methylation status or protein expression. In summary, the information contained in dbCRAF is more comprehensive.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>The statistic and comparison of dbCRSR and dbCRAF databases</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Term</th>
              <th rowspan="1" colspan="1">dbCRSR</th>
              <th rowspan="1" colspan="1">dbCRAF</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Database function</td>
              <td rowspan="1" colspan="1">Download, search</td>
              <td rowspan="1" colspan="1">Download, search, analysis</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication source</td>
              <td rowspan="1" colspan="1">PubMed</td>
              <td rowspan="1" colspan="1">PubMed</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication date</td>
              <td rowspan="1" colspan="1">January 2008–October 2017</td>
              <td rowspan="1" colspan="1">January 2000–February 2022</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Publication number</td>
              <td rowspan="1" colspan="1">1,072</td>
              <td rowspan="1" colspan="1">2,670</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Association number</td>
              <td rowspan="1" colspan="1">1,132</td>
              <td rowspan="1" colspan="1">4,448</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Mechanism</td>
              <td rowspan="1" colspan="1">Experiment (RS<sup>a</sup>)</td>
              <td rowspan="1" colspan="1">Experiment (RS/RR<sup>b</sup>), prediction</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Factor type</td>
              <td rowspan="1" colspan="1">mRNA (395), miRNA (119), compound (306)</td>
              <td rowspan="1" colspan="1">Gene (1,677), protein (49), radiosensitizer (612)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T1TFN1">
            <p><sup>a</sup>Radiosensitivity.</p>
          </fn>
          <fn id="T1TFN2">
            <p><sup>b</sup>Radioresistance.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>In addition, we made three findings by analyzing the 4,448 associations recorded in dbCRAF. First, the number of studies that focused on molecular mechanisms of radiation response showed an increasing trend year by year (Figure <xref rid="F1" ref-type="fig">1A</xref>). This indicates the growing interest in understanding the molecular mechanisms of radiation response and its potential applications in cancer treatment. Meanwhile, recent studies published since 2018 have integrated the analysis of large genomic or transcriptome datasets with biological experiments to efficiently screen and verify genes of interest. This approach eliminated the limitations imposed by prior knowledge or assumptions and provided stronger evidence for identifying potential new associations between factors and cancer. Second, more than half of the associations were related to head and neck neoplasms, lung neoplasms, and breast neoplasms (Figure <xref rid="F1" ref-type="fig">1B</xref>), which might be due to their higher incidence or the wider use of RT options and thus leading to more relevant studies (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B34" ref-type="bibr">34–36</xref>). Third, the largest number of factors involved in regulating cancer radiation response were genes, followed by radiosensitizers (Figure <xref rid="F1" ref-type="fig">1C</xref>). Lastly, we separately counted the five categories of genes and found that in addition to protein-coding genes, there has been an increasing amount of ncRNAs documented in the radiation response-related literature (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Summary of dbCRAF contents. (<bold>A</bold>) Statistics of publication information. (<bold>B</bold>) Statistics of association data with each cancer type. (<bold>C</bold>) Statistics of association data with each kind of factor.</p>
        </caption>
        <graphic xlink:href="zcae008fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Hot protein-coding gene and enriched pathways</title>
      <p>After counting 2,658 associations between coding gene and cancer, we found a total of 1,308 coding genes. Among them, <italic toggle="yes">HIF1A</italic>, <italic toggle="yes">EGFR</italic>, and <italic toggle="yes">ATM</italic> were the most extensively studied coding genes, and their expression levels could influence the response of multiple tumors to radiation (Figure <xref rid="F2" ref-type="fig">2A</xref>). Next, we grouped all coding genes (793 versus 666) collected in ‘Experiment’ and ‘Prediction’ articles respectively, and obtained 151 genes shared between them (Figure <xref rid="F2" ref-type="fig">2B</xref>). This indicates that both biological experiments and computational methods have identified these 151 genes as potential genetic biomarkers for prognosis, radiosensitivity or radioresistance in human cancer. This finding suggests the possibility of optimizing RT effects based on a patient's genomic profiles and intrinsic radiosensitivity (<xref rid="B39" ref-type="bibr">39</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Overview of protein-coding gene-cancer associations. (<bold>A</bold>) Word cloud of all protein-coding genes, where there is more literature evidence for genes are displayed using a larger font size. (<bold>B</bold>) Number of coding genes derived from Experiment or Prediction publications. (<bold>C</bold>) The top 20 KEGG enrichment pathways of coding genes with experimental evidence (793 genes) or only computational analysis results (515 genes).</p>
        </caption>
        <graphic xlink:href="zcae008fig2" position="float"/>
      </fig>
      <p>Additionally, we analyzed 515 coding genes related to cancer prognosis identified in the ‘Prediction’ articles but not in the ‘Experiment’ articles to uncover more potential genetic biomarkers. Specifically, we performed the KEGG pathway enrichment analysis on the two groups of coding genes (793 versus 515) with or without experimental evidence of regulating radiation response. The results showed that four pathways were the same in both groups of genes, including IL-17 signaling pathway, neurodegeneration-multiple diseases pathways, pathways in cancer, and proteoglycans in cancer (Figure <xref rid="F2" ref-type="fig">2C</xref>). In summary, 137 of the 515 coding genes are involved in one or more of these four pathways (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>), and it is likely that they regulate radiosensitivity, radioresistance or prognosis in cancer through their involvement in these functional pathways.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Noncoding RNA, radiosensitizer and their target genes analysis</title>
      <p>Non-coding RNAs and radiosensitizers typically exert regulatory function in radiation response via interacting with target genes. Therefore, we collected and analyzed interaction data of ncRNAs and radiosensitizers related to radiation response from various databases (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). First, we counted the most studied miRNAs, lncRNAs and radiosensitizers based on association data documented in dbCRAF. As shown in Figure <xref rid="F3" ref-type="fig">3A</xref>, the top four ncRNAs and radiosensitizers were all involved in modulating radiation response in one or more cancers. Notably, there were only 31 associations between circRNA and cancer, making it difficult to sort circRNAs according to the study frequency. Second, we integrated all target genes and interaction data of ncRNAs and radiosensitizers linked with radiation response, including miRNA-target interactions, lncRNA-target interactions, circRNA–target interactions and radiosensitizer-target interactions. Interestingly, almost 25% of the target genes have been documented to be associated with radiation response (Figure <xref rid="F3" ref-type="fig">3B</xref>). Third, we counted the top 20 target genes that appeared most frequently in the interaction data and collected evidence for their regulation of radiation response. We hypothesized that target genes that appear more frequently in the interaction data are more likely to regulate radiosensitivity or radioresistance. Coincidentally, 19 of the top 20 target genes have been experimentally confirmed to regulate the radiation response (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>), with only the <italic toggle="yes">FOXO1</italic> gene lacking study evidence.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Statistics related to non-coding RNAs, radiosensitizers and their target interactions. (<bold>A</bold>) Statistics of the associations about top four miRNAs, lncRNAs and radiosensitizers, where more frequent associations are displayed using a thicker line. (<bold>B</bold>) Venn diagram of genes recorded in dbCRAF and all target genes. (<bold>C</bold>) Sankey diagram of FOXO1–miRNA–cancer associations.</p>
        </caption>
        <graphic xlink:href="zcae008fig3" position="float"/>
      </fig>
      <p>Therefore, we combined miRNA-target (<italic toggle="yes">FOXO1</italic>) interactions and relevant associations between miRNA and cancer recorded in dbCRAF to map <italic toggle="yes">FOXO1</italic>-miRNA-cancer associations. The results showed that <italic toggle="yes">FOXO1</italic> may be associated with radiation responses in lung neoplasms and head and neck neoplasms (Figure <xref rid="F3" ref-type="fig">3C</xref>). Although there is no direct evidence suggesting that <italic toggle="yes">FOXO1</italic> regulates the radiation response of cancer cells, <italic toggle="yes">FOXO1</italic> is still an important factor in cancer processes based on its inclusion in the oncogene and tumor suppressor gene list from the Cancer Gene Census project (<xref rid="B40" ref-type="bibr">40</xref>). Additionally, Zhou <italic toggle="yes">et al.</italic> found that <italic toggle="yes">TCF19</italic> could promote cell proliferation in non‐small cell lung cancer by inhibiting <italic toggle="yes">FOXO1</italic> (<xref rid="B41" ref-type="bibr">41</xref>). Gong <italic toggle="yes">et al.</italic> also showed that the <italic toggle="yes">AKBA</italic> gene inhibited radioresistance in lung cancer through the regulation of the <italic toggle="yes">AKT</italic>/<italic toggle="yes">FOXO1</italic>/<italic toggle="yes">p21</italic> axis (<xref rid="B42" ref-type="bibr">42</xref>). These findings support our conclusion that <italic toggle="yes">FOXO1</italic> may be closely related to the occurrence and prognosis of RT in lung cancer.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Key dbCRAF modules and user cases</title>
      <p>dbCRAF provides a comprehensive collection of high-quality data, including association data between factors and radiation response in cancer as well as interaction data between factors and target genes. All data are freely available through the Download module, and users can browse and analyze the data using the Data-Matrix, Search, and Analysis modules on the dbCRAF website (<ext-link xlink:href="http://dbCRAF.xialab.info/" ext-link-type="uri">http://dbCRAF.xialab.info/</ext-link>), as shown in Figure <xref rid="F4" ref-type="fig">4</xref>.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>Schematic of dbCRAF.</p>
        </caption>
        <graphic xlink:href="zcae008fig4" position="float"/>
      </fig>
      <p>The ‘Data-Matrix’ page is an interactive and digitized table organized by factors (rows) associated with radiation response and cancer types (columns), allowing users to quickly navigate all association entries.</p>
      <p>For the Search page, dbCRAF provides user-friendly search options supporting automatic retrieval of association data recorded in dbCRAF under multiple cancer types. In addition, users can query the related data with different evidence in three ways: ‘By All’, ‘By Experiment’ and ‘By Prediction’. Furthermore, users can click the corresponding entry to view all detailed information, such as key sentences and biological experiment settings.</p>
      <p>On the Analysis page, dbCRAF supports four practical analysis functions to answer common biological questions. Users can perform word cloud, KEGG pathway enrichment analysis, and interaction network visualization using a list of factors related to radiation response along with their interaction data. Kaplan-Meier survival analysis is implemented with the miRNA-seq, mRNA-seq and clinical data of cancer patients treated with RT in the TCGA database.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>To the best of our knowledge, dbCRAF is the first database to furnish association data between factor and human cancer related to multiple radiation response regulatory mechanisms, including radiosensitivity, radioresistance, and prognosis of RT in cancer patients. At the same time, we gathered the interaction data concerning ncRNAs and radiosensitizers linked to radiation response. On top of that, dbCRAF allows users to analyze the above information, and provides an all-in-one service for the retrieval, analysis, and visualization of human cancer radiation response factors related to human cancer.</p>
    <p>For this study, we ran statistical analyses of association data retrieved from the PubMed literature, interaction data and target genes derived from multiple databases, respectively, to provide more guidance for researchers. Moreover, we found that out of the 666 coding genes related to tumor RT prognosis, a total of 151 genes had been validated by over-expression or knock-down assays. These assays have demonstrated their potential influence on the radiosensitivity or radioresistance of cancer cell lines. Therefore, it is essential to perform biological experiments on the remaining 515 genes to investigate their regulatory mechanism of response to radiation in human cancer cells. Additionally, regarding the data of miRNA-target interactions, we observed that hsa-miR-195–5p interacted with <italic toggle="yes">BCL2</italic>, the target gene with the most interaction data (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>). Interestingly, earlier studies revealed that hsa-miR-195-5p could enhance the radiosensitivity of breast cancer cells by repressing the expression of <italic toggle="yes">BCL2</italic> (<xref rid="B43" ref-type="bibr">43</xref>). Consequently, it is feasible to discover more potential biomarkers of radiation response by utilizing both information including the associations between factor and cancer in dbCRAF and corresponding interactions between factor and target gene.</p>
    <p>This work also has several limitations that require further exploration. On the one hand, the current database lacks information on radiation toxicity, the change of radiosensitivity, treatment options and machines. It is necessary to explore and include this additional information from relevant literature or databases in the future to enhance the understanding of radiation response. On the other hand, we observed that more than half of the associations are linked to head and neck neoplasms, lung neoplasms and breast neoplasms. This disproportionate distribution may introduce bias in the database and the biological information it contains. To address this issue, we are considering implementing mechanisms such as weighting, where cancer types with fewer associations are given greater weight when inferring potential associations between genes and radiation response in cancer. Furthermore, it is crucial to supplement associations of cancer types with limited data by incorporating information from additional sources like Web of Science and Scopus. These efforts will contribute to a more comprehensive representation of radiation response and help mitigate potential bias across various types of cancer.</p>
    <p>In conclusion, with the collated data and the implementation of four online analysis tools, dbCRAF is not only an integrated resource, but also a web server for mining the potential molecular mechanisms of radiation response. The data and the functions of dbCRAF may be provide new perspectives on the development of RT therapeutics for human cancer.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>zcae008_supplemental_file</label>
      <media xlink:href="zcae008_supplemental_file.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>The authors acknowledge the High-performance Computing Platform of Anhui University for providing computing resources. We would like to thank the Xia laboratory members for their participation in the data collection in this work.</p>
    <p><italic toggle="yes">Author contributions</italic>: J. Liu: Data curation, Methodology, Writing-original draft. J. Li.: Database design, Writing - original draft. F. Jin: Database design. Q. Li: Methodology. G. Zhao: Writing-review &amp; editing. L. Wu: Writing-review &amp; editing. X. Li: Supervision, Writing-review &amp; editing. J. Xia: Conceptualization, Supervision, Writing-review &amp; editing. N. Cheng: Conceptualization, Supervision, Writing-review &amp; editing.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>No new data were generated or analysed in support of this research.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/narcancer/article-lookup/doi/10.1093/narcan/zcae008#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Cancer Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Natural Science Foundation of China [11835014, U22A2038]; Natural Science Foundation of Anhui Province [2208085QF193]; National Science Fund for Excellent Young Scholars [12122510].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sung</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J.</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Laversanne</surname><given-names>M.</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bray</surname><given-names>F.</given-names></string-name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin.</source><year>2021</year>; <volume>71</volume>:<fpage>209</fpage>–<lpage>249</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bray</surname><given-names>F.</given-names></string-name>, <string-name><surname>Laversanne</surname><given-names>M.</given-names></string-name>, <string-name><surname>Weiderpass</surname><given-names>E.</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I.</given-names></string-name></person-group><article-title>The ever-increasing importance of cancer as a leading cause of premature death worldwide</article-title>. <source>Cancer-Am Cancer Soc.</source><year>2021</year>; <volume>127</volume>:<fpage>3029</fpage>–<lpage>3030</lpage>.</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>K.</given-names></string-name>, <string-name><surname>Tepper</surname><given-names>J.E.</given-names></string-name></person-group><article-title>Radiation therapy-associated toxicity: etiology, management, and prevention</article-title>. <source>CA Cancer J Clin.</source><year>2021</year>; <volume>71</volume>:<fpage>437</fpage>–<lpage>454</lpage>.<pub-id pub-id-type="pmid">34255347</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bentzen</surname><given-names>S.M.</given-names></string-name></person-group><article-title>Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology</article-title>. <source>Nat. Rev. Cancer</source>. <year>2006</year>; <volume>6</volume>:<fpage>702</fpage>–<lpage>713</lpage>.<pub-id pub-id-type="pmid">16929324</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quon</surname><given-names>H.</given-names></string-name>, <string-name><surname>McNutt</surname><given-names>T.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bowers</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Lakshminarayanan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Han</surname><given-names>P.J.</given-names></string-name>, <string-name><surname>Hui</surname><given-names>X.</given-names></string-name>, <string-name><surname>Moore</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Needs and challenges for radiation oncology in the era of precision medicine</article-title>. <source>Int. J Radiat Oncol.</source><year>2019</year>; <volume>103</volume>:<fpage>809</fpage>–<lpage>817</lpage>.</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bernier</surname><given-names>J.</given-names></string-name></person-group><article-title>Precision medicine for early breast cancer radiotherapy: opening up new horizons?</article-title>. <source>Crit. Rev. Oncol. Hemat.</source><year>2017</year>; <volume>113</volume>:<fpage>79</fpage>–<lpage>82</lpage>.</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>H.H.W.</given-names></string-name>, <string-name><surname>Kuo</surname><given-names>M.T.</given-names></string-name></person-group><article-title>Improving radiotherapy in cancer treatment: promises and challenges</article-title>. <source>Oncotarget</source>. <year>2017</year>; <volume>8</volume>:<fpage>62742</fpage>–<lpage>62758</lpage>.<pub-id pub-id-type="pmid">28977985</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marks</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Yorke</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ten Haken</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Constine</surname><given-names>L.S.</given-names></string-name>, <string-name><surname>Eisbruch</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bentzen</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Nam</surname><given-names>J.</given-names></string-name>, <string-name><surname>Deasy</surname><given-names>J.O.</given-names></string-name></person-group><article-title>Use of normal tissue complication probability models in the clinic</article-title>. <source>Int. J Radiat. Oncol.</source><year>2010</year>; <volume>76</volume>:<fpage>S10</fpage>–<lpage>S19</lpage>.</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Galeaz</surname><given-names>C.</given-names></string-name>, <string-name><surname>Totis</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bisio</surname><given-names>A.</given-names></string-name></person-group><article-title>Radiation resistance: a matter of transcription factors</article-title>. <source>Front. Oncol.</source><year>2021</year>; <volume>11</volume>:<fpage>662840</fpage>.<pub-id pub-id-type="pmid">34141616</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>F.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name></person-group><article-title>Radiation-induced cell death and its mechanisms</article-title>. <source>Health Phys.</source><year>2022</year>; <volume>123</volume>:<fpage>376</fpage>–<lpage>386</lpage>.<pub-id pub-id-type="pmid">36069830</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xi</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>D.H.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>An omics-to-omics joint knowledge association subtensor model for radiogenomics cross-modal modules from genomics and ultrasonic images of breast cancers</article-title>. <source>Comput. Biol. Med.</source><year>2023</year>; <volume>155</volume>:<fpage>106672</fpage>.<pub-id pub-id-type="pmid">36805226</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>F.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name></person-group><article-title>PVT1 mediates cell proliferation, apoptosis and radioresistance in nasopharyngeal carcinoma through regulating miR-515-5p/PIK3CA Axis</article-title>. <source>Cancer Manag. Res.</source><year>2020</year>; <volume>12</volume>:<fpage>10077</fpage>–<lpage>10090</lpage>.<pub-id pub-id-type="pmid">33116864</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>P.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y.M.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name></person-group><article-title>Circ_0067835 knockdown enhances the radiosensitivity of colorectal cancer by miR-296-5p/IGF1R axis</article-title>. <source>Oncotargets Ther.</source><year>2021</year>; <volume>14</volume>:<fpage>491</fpage>–<lpage>502</lpage>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wen</surname><given-names>P.B.</given-names></string-name>, <string-name><surname>Xia</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>X.B.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>B.</given-names></string-name>, <string-name><surname>Tao</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>G.P.</given-names></string-name></person-group><article-title>dbCRSR: a manually curated database for regulation of cancer radiosensitivity</article-title>. <source>Database-Oxford</source>. <year>2018</year>; <volume>2018</volume>:<fpage>bay049</fpage>.<pub-id pub-id-type="pmid">29860480</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Principe</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zapater-Latorre</surname><given-names>E.</given-names></string-name>, <string-name><surname>Arribas</surname><given-names>L.</given-names></string-name>, <string-name><surname>Garcia-Miragall</surname><given-names>E.</given-names></string-name>, <string-name><surname>Bagan</surname><given-names>J.</given-names></string-name></person-group><article-title>Salivary IL-8 as a putative predictive biomarker of radiotherapy response in head and neck cancer patients</article-title>. <source>Clin. Oral. Invest.</source><year>2022</year>; <volume>26</volume>:<fpage>437</fpage>–<lpage>448</lpage>.</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>L.</given-names></string-name>, <string-name><surname>Geng</surname><given-names>R.R.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y.F.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Z.X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S.B.</given-names></string-name></person-group><article-title>An 11-gene signature based on treatment responsiveness pedicts radiation therapy survival benefit among breast cancer patients</article-title>. <source>Front. Oncol.</source><year>2022</year>; <volume>11</volume>:<fpage>816053</fpage>.<pub-id pub-id-type="pmid">35071020</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Song</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Gu</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Z.Q.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>X.C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Q.Y.</given-names></string-name></person-group><article-title>A radioresponse-related lncRNA biomarker signature for risk classification and prognosis prediction in non-small-cell lung cancer</article-title>. <source>J. Oncol.</source><year>2021</year>; <volume>2021</volume>:<fpage>4338838</fpage>.<pub-id pub-id-type="pmid">34594376</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>C.D.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y.</given-names></string-name></person-group><article-title>RTPDB: a database providing associations between genetic variation or expression and cancer prognosis with radiotherapy-based treatment</article-title>. <source>Database</source>. <year>2018</year>; <volume>2018</volume>:<fpage>bay118</fpage>.<pub-id pub-id-type="pmid">30376049</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xi</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>X.G.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>A.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.L.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>Inferring subgroup-specific driver genes from heterogeneous cancer samples via subspace learning with subgroup indication</article-title>. <source>Bioinformatics</source>. <year>2020</year>; <volume>36</volume>:<fpage>1855</fpage>–<lpage>1863</lpage>.<pub-id pub-id-type="pmid">31626284</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Allot</surname><given-names>A.</given-names></string-name>, <string-name><surname>Leaman</surname><given-names>R.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Z.Y.</given-names></string-name></person-group><article-title>PubTator central: automated concept annotation for biomedical full text articles</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>W587</fpage>–<lpage>W593</lpage>.<pub-id pub-id-type="pmid">31114887</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tweedie</surname><given-names>S.</given-names></string-name>, <string-name><surname>Braschi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>T.E.M.</given-names></string-name>, <string-name><surname>Seal</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Yates</surname><given-names>B.</given-names></string-name>, <string-name><surname>Bruford</surname><given-names>E.A.</given-names></string-name></person-group><article-title>Genenames.org: the HGNC and VGNC resources in 2021</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D939</fpage>–<lpage>D946</lpage>.<pub-id pub-id-type="pmid">33152070</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lipscomb</surname><given-names>C.E.J.B.o.t.M.L.A.</given-names></string-name></person-group><article-title>Medical subject headings (MeSH)</article-title>. <source>Bull. Med. Libr. Assoc.</source><year>2000</year>; <volume>88</volume>:<fpage>265</fpage>–<lpage>266</lpage>.<pub-id pub-id-type="pmid">10928714</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Safran</surname><given-names>M.</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Twik</surname><given-names>M.</given-names></string-name>, <string-name><surname>BarShir</surname><given-names>R.</given-names></string-name>, <string-name><surname>Stein</surname><given-names>T.I.</given-names></string-name>, <string-name><surname>Dahary</surname><given-names>D.</given-names></string-name>, <string-name><surname>Fishilevich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lancet</surname><given-names>D</given-names></string-name></person-group><source>Practical Guide to Life Science Databases</source>. <year>2021</year>; <publisher-name>Springer</publisher-name><fpage>27</fpage>–<lpage>56</lpage>.</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y.C.D.</given-names></string-name>, <string-name><surname>Cui</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y.X.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>J.Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.L.</given-names></string-name>, <string-name><surname>Wen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zuo</surname><given-names>H.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D222</fpage>–<lpage>D230</lpage>.<pub-id pub-id-type="pmid">34850920</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P.P.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>Q.H.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>W.Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>Q.H.</given-names></string-name></person-group><article-title>LncRNA2Target v2.0: a comprehensive database for target genes of lncRNAs in human and mouse</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D140</fpage>–<lpage>D144</lpage>.<pub-id pub-id-type="pmid">30380072</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dudekulay</surname><given-names>D.B.</given-names></string-name>, <string-name><surname>Panda</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Grammatikakis</surname><given-names>I.</given-names></string-name>, <string-name><surname>De</surname><given-names>S.</given-names></string-name>, <string-name><surname>Abdelmohsen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Gorospe</surname><given-names>M.</given-names></string-name></person-group><article-title>CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs</article-title>. <source>Rna Biol.</source><year>2016</year>; <volume>13</volume>:<fpage>34</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">26669964</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B.B.</given-names></string-name>, <string-name><surname>Ding</surname><given-names>X.M.</given-names></string-name></person-group><article-title>Circbank: a comprehensive database for circRNA with standard nomenclature</article-title>. <source>Rna Biol.</source><year>2019</year>; <volume>16</volume>:<fpage>899</fpage>–<lpage>905</lpage>.<pub-id pub-id-type="pmid">31023147</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whirl-Carrillo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huddart</surname><given-names>R.</given-names></string-name>, <string-name><surname>Gong</surname><given-names>L.</given-names></string-name>, <string-name><surname>Sangkuhl</surname><given-names>K.</given-names></string-name>, <string-name><surname>Thorn</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Whaley</surname><given-names>R.</given-names></string-name>, <string-name><surname>Klein</surname><given-names>T.E.</given-names></string-name></person-group><article-title>An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine</article-title>. <source>Clin. Pharmacol. Ther.</source><year>2021</year>; <volume>110</volume>:<fpage>563</fpage>–<lpage>572</lpage>.<pub-id pub-id-type="pmid">34216021</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X.D.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname><given-names>J.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szklarczyk</surname><given-names>D.</given-names></string-name>, <string-name><surname>Gable</surname><given-names>A.L.</given-names></string-name>, <string-name><surname>Nastou</surname><given-names>K.C.</given-names></string-name>, <string-name><surname>Lyon</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kirsch</surname><given-names>R.</given-names></string-name>, <string-name><surname>Pyysalo</surname><given-names>S.</given-names></string-name>, <string-name><surname>Doncheva</surname><given-names>N.T.</given-names></string-name>, <string-name><surname>Legeay</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>T.</given-names></string-name>, <string-name><surname>Bork</surname><given-names>P.</given-names></string-name></person-group><article-title>The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D605</fpage>–<lpage>D612</lpage>.<pub-id pub-id-type="pmid">33237311</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Goto</surname><given-names>S.</given-names></string-name></person-group><article-title>KEGG: Kyoto encyclopedia of genes and genomes</article-title>. <source>Nucleic Acids Res.</source><year>2000</year>; <volume>28</volume>:<fpage>27</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">10592173</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tomczak</surname><given-names>K.</given-names></string-name>, <string-name><surname>Czerwińska</surname><given-names>P.</given-names></string-name>, <string-name><surname>Wiznerowicz</surname><given-names>M.</given-names></string-name></person-group><article-title>Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge</article-title>. <source>Contemp Oncol.</source><year>2015</year>; <volume>2015</volume>:<fpage>68</fpage>–<lpage>77</lpage>.</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chow</surname><given-names>L.Q.</given-names></string-name></person-group><article-title>Head and neck cancer</article-title>. <source>N. Engl. J Med.</source><year>2020</year>; <volume>382</volume>:<fpage>60</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">31893516</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lemjabbar-Alaoui</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hassan</surname><given-names>O.U.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.W.</given-names></string-name>, <string-name><surname>Buchanan</surname><given-names>P.</given-names></string-name></person-group><article-title>Lung cancer: biology and treatment options</article-title>. <source>Bba-Rev Cancer</source>. <year>2015</year>; <volume>1856</volume>:<fpage>189</fpage>–<lpage>210</lpage>.</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Al-Mahmood</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sapiezynski</surname><given-names>J.</given-names></string-name>, <string-name><surname>Garbuzenko</surname><given-names>O.B.</given-names></string-name>, <string-name><surname>Minko</surname><given-names>T.</given-names></string-name></person-group><article-title>Metastatic and triple-negative breast cancer: challenges and treatment options</article-title>. <source>Drug Deliv. Transl. Re</source>. <year>2018</year>; <volume>8</volume>:<fpage>1483</fpage>–<lpage>1507</lpage>.</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ebahimzadeh</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shoorei</surname><given-names>H.</given-names></string-name>, <string-name><surname>Mousavinejad</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Anamag</surname><given-names>F.T.</given-names></string-name>, <string-name><surname>Dinger</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Taheri</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ghafouri-Fard</surname><given-names>S.</given-names></string-name></person-group><article-title>Emerging role of non-coding RNAs in response of cancer cells to radiotherapy</article-title>. <source>Pathol. Res. Pract.</source><year>2021</year>; <volume>218</volume>:<fpage>153327</fpage>.<pub-id pub-id-type="pmid">33422780</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cui</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Li</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>D.L.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L.W.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.W.</given-names></string-name></person-group><article-title>Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance</article-title>. <source>Mol. Cancer</source>. <year>2020</year>; <volume>19</volume>:<fpage>58</fpage>.<pub-id pub-id-type="pmid">32171304</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grimes</surname><given-names>D.R.</given-names></string-name></person-group><article-title>Limitations of the radiosensitivity index as a direct prognostic marker</article-title>. <source>Lancet Oncol.</source><year>2022</year>; <volume>23</volume>:<fpage>1352</fpage>–<lpage>1353</lpage>.<pub-id pub-id-type="pmid">36328006</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sondka</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Bamford</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>C.G.</given-names></string-name>, <string-name><surname>Ward</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Dunham</surname><given-names>I.</given-names></string-name>, <string-name><surname>Forbes</surname><given-names>S.A.</given-names></string-name></person-group><article-title>The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers</article-title>. <source>Nat. Rev. Cancer</source>. <year>2018</year>; <volume>18</volume>:<fpage>696</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="pmid">30293088</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>Z.H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>G.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D.K.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>R.Q.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>TCF19 contributes to cell proliferation of non-small cell lung cancer by inhibiting FOXO1</article-title>. <source>Cell Biol. Int.</source><year>2019</year>; <volume>43</volume>:<fpage>1416</fpage>–<lpage>1424</lpage>.<pub-id pub-id-type="pmid">31141247</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gong</surname><given-names>C.</given-names></string-name>, <string-name><surname>Li</surname><given-names>W.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>L.W.</given-names></string-name></person-group><article-title>AKBA inhibits radiotherapy resistance in lung cancer by inhibiting maspin methylation and regulating the AKT/FOXO1/p21 axis</article-title>. <source>J. Radiat. Res.</source><year>2022</year>; <volume>64</volume>:<fpage>33</fpage>–<lpage>43</lpage>.</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Xiong</surname><given-names>W.</given-names></string-name>, <string-name><surname>He</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>W.</given-names></string-name></person-group><article-title>Upregulation of miR-195 enhances the radiosensitivity of breast cancer cells through the inhibition of BCL-2</article-title>. <source>Int. J. Clin. Exp. Med.</source><year>2015</year>; <volume>8</volume>:<fpage>9142</fpage>.<pub-id pub-id-type="pmid">26309570</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
